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Sleep is a complex behavior and it is hierarchically regulated involving several brain 
regions, neurotransmitters, and genes that co-operate in building modulatory 
mechanisms aimed at controlling and maintaining sleep. Specifically, this thesis attempts 
to address/understand how genomic imprinting, which affect a subset of genes in 
mammals resulting in a monoallelic expression, may regulate sleep.   
 
One of the main brain regions involved in sleep regulation is the hypothalamus. Within 
the hypothalamic region imprinted genes are highly expressed. Interestingly, it has been 
described that hypothalamic insufficiency (notably, the word “insufficiency” referred to 
the hypothalamus in this thesis always introduces the hypothalamic issues of the PWS) 
caused by lack of paternal expression of chromosome 15q11-q13, leads to Prader-Willi 
syndrome (PWS). Specifically, the microdeletion of the small nuclear ribonucleic acid 
(RNA)-116 (SNORD116) cluster within the PWS locus plays a major role in developing the 
main endophenotypes that characterize this syndrome (i.e. REM sleep dysfunction, 
hyperphagia and temperature instability). However, what could be the role of the 
paternally imprinted gene Snord116 in the hypothalamic function is unknown. 
Additionally, is still unclear the specific contribution of the Snord116 gene in developing 
the PWS symptoms. Since these unresolved points my research has been split into three 
parts: 
 
In the first part of this research, it has been shown that the paternally imprinted gene 
Snord116 plays a crucial role in the formation and organization of the orexin (OX) and 
melanin concentrating hormone (MCH) systems, the two main neuro-modulatory systems 
within the lateral hypothalamus (LH). Moreover, a compromised neuronal dynamic in the 
LH and a sleep-wake regulation of mice with paternal deletion of Snord116 (PWScrm+/p-) is 
observed. This abnormal neuronal dynamic is accompanied by a significant reduction in 
OX neurons in the LH of mutant mice. For this reason, it is proposed that the dysregulation 
of rapid eye movement (REM) sleep, food intake and temperature control observed in 
PWS mice are potentially due to this imbalance between OX- and MCH-expressing 
neurons in the LH as observed in mutant mice.  




electrophysiological components of sleep, such as REM sleep features and sleep spindles 
during non-REM sleep. Indeed, REM sleep is thought to contribute to neuronal network 
formation early in brain development, while spindles are markers of thalamocortical 
processes. In neurodevelopmental disorders both sleep structures (REM and sleep 
spindles) are often compromised and this influence functional properties of cortical 
neurons. These results indicate that REM sleep properties and its occurrence (REM sleep 
episodes classified as short-and long REM sleep episode) throughout the sleep-wake 
cycles are selectively influenced by the Snord116 gene in mice. Moreover, the specific 
abnormalities in sleep spindles in PWS model systems, indicate that these sleep features 
may be translated as potential biomarkers in human PWS sufferers. 
In the third part of this research, it has been proposed a new therapeutic approach for 
PWS patients aiming to ameliorate the sleep phenotypes that significantly compromise 
the quality of life of these patients. Pitolisant (a wake-promoting drug) was orally 
administrated in mice carrying the paternal deletion of the Snord116 gene that are 
affected by REM sleep alteration coupled with a reduction of the OX neurons.  
Overall the results of this research show that Pitolisant ameliorates the REM sleep 
alteration in these mice, although other studies are needed to clarify whether this drug 
may be easily translated/used in clinics. 
 
In conclusion, this thesis provides support for the important role of Snord116 in the 
regulation of REM sleep and its propensity and its regulatory mechanisms in the 
hypothalamus. Finally, a new pharmacological approach for PWS by using Pitolisant has 









Sleep is a universal and physiological phenomenon which is extremely important to keep 
our brain and body healthy. Indeed, sleep alterations are implicated in several human 
diseases, however, how sleep is regulated is not completely understood.  
The recognition of sleep behavior across multiple lines of the animal kingdom strongly 
suggests the presence of a shared or universal function. Sleep is also characterized by a 
homeostatic regulatory capacity that includes compensation with increased sleep 
intensity or duration after loss [1], in all species that have been systematically examined 
so far [2]–[5]. Sleep is usually defined in most animal species  by behavioral criteria  [6]. 
These criteria include species-specific posture, behavioral quiescence and elevated 
arousal threshold. Sleep can also be defined as reduced responsiveness to external stimuli 
and relative inactivity with loss of consciousness [7]. Since sleep is a complex behavior it 
is regulated in a hierarchical way, that goes from a more general (biological and 
homeostatic) to a more complex and specific organization represented by genetic and 
epigenetic regulations of sleep. Specifically, in this thesis we investigated how an 
epigenetic phenomenon, namely genomic imprinting, may regulate sleep.  
Since one of the most important epigenetic dysfunctions in humans is represented by 
Prader Willi Syndrome (PWS), where approximately 76% of PWS patients exhibit 
abnormal sleep [8], we used this model to understand the role of the imprinted genes in 
the regulation of sleep.  
Overall, I believe that the results of this thesis may bring a new understanding of how 
genomic imprinting may play a crucial role in the regulation of sleep, therefore opening 






1.1.1 Sleep characterization and sub-stages 
Sleep is characterized by precise physiological and behavioral features; indeed, using 
electroencephalography (EEG) combined with electromyography (EMG) and 
electrooculogram (EOG) It is possible to identify different sleep states. The vast majority 
of endothermic (warm-blooded) birds and mammals exhibit three distinct type of sleep 
states: non-rapid eye movement sleep (non-REM) and rapid eye movement sleep (REM) 
and wakefulness that alternate cyclically over the 24-hour. These three sleep-wake states 
have specific characteristics; including variation in brain waveforms, eye movements and 
muscle tone. These three stages are very similar between humans and rodents although 
some differences have been described. See Box 1 for more details between humans and 
rodent sleep. Notably, in this thesis all experiments were performed on mice. 
The three main sleep stages and how they are defined are detailed below. 
 
Non-REM state 
Both in humans and rodents the non-REM state is characterized by generalized 
immobility, a reduced muscle activity, regular respiration and heart rate, and typically by 
a decrease of faster components of EEG, a state of cortical EEG slowing, often with high 
amplitude EEG slow waves [9], [10]. The EEG shows predominantly frequency of 4 to 7 Hz 
activity and irregularly spaced bursts of slow waves [11]. These regular occurrences of 
local and global slow cortical oscillations include bursts of oscillatory brain activity in the 
sigma frequency (12 – 15 Hz) named sleep spindles. Usually these events are isolated and 
appear both spontaneously as well as on the application of alerting stimuli at irregular 
intervals. Sleep spindles are bursts of activity usually last from 0.5 and 2 seconds. They are 
characteristic transient features of the EEG sleep (spindles represent an EEG 
graphoelement typical of sleep) [12]. Dysregulation of spindle properties is a sensitive 
indicator of thalamocortical and neuromodulator dysfunction in many diseases, including 
neurodevelopmental disorders [13]. Non-REM sleep also includes K-complex waveforms 
(frequency between 0.1 and 1 Hz) and high – amplitude slow-wave activity (SWA at 
around 0.5 – 4.5 Hz) [14]. Non-REM sleep in humans, accounting for about 80% of sleep 




intensity and duration across time [7].  
Non-REM sleep is usually divided into three stages [7] in humans, while this classification 
in rodents is difficult to see. However, for differences in the sleep architecture between 
humans and rodents see Box 1. The three stages of non-REM sleep in humans represent 
the following characteristics: Stage I represents a transition from wakefulness and it 
occupies 5 to 10% of normal sleep. Stage II is characterized by the repetitive presence of 
distinctive sleep spindles and K-complex waveforms [7]. Stage III is the deepest state of 
non-REM sleep and it is characterized by SWA. In this stage it is most difficult to awaken 
people. Interestingly, SWA is considered as a marker for sleep intensity and pressure [10], 
[15]. Indeed, the longer a subject has been awake the higher the spectral power in the 
slow wave range of the EEG in subsequent sleep, which declines during the course of sleep 
[16]. This increase of SWA is accompanied by a decrease in regional cerebral blood flow 
and heart rate and a reduction in cerebral glucose utilization, indicating a lower metabolic 
demand [17]. For this reason it has been suggested that SWA plays a role in the restorative 
process of sleep [10], [15], [18]. 
 
REM state 
REM sleep is also known as paradoxical sleep, it qualifies as a sleep stage (as well as a 
behavioral state) and occurs for about 20% of total sleep time. It only occurs after period 
of non-REM sleep and in humans it becomes more intensive and extensive towards the 
end of the sleep period [7]. Even though the REM state is characterized by desynchronized 
brain waves (low-voltage, high-frequency) and cortical EEG activation resembling 
wakefulness, it differs from the wake state by the presence of a generalized skeletal 
muscle atonia with intermittent muscle twitches of the distal extremities, penile or clitoral 
erections and increased respiratory and heart rate variability [19]. During REM sleep, 
there is also the presence of vivid dreams in humans [20], [21], loss of thermoregulatory 
defense and the appearance of rapid eye movements [22]. For this reason, REM sleep is 
concisely defined as a highly activated brain in a paralyzed body [23]. The 
electrophysiological features of the REM state show oscillation in the range of theta 
frequencies (5 – 8 Hz) and slow alpha activity that arises mostly from the hippocampus. 
However, these theta oscillations have been found in cortical structures too, but none of 




state is still not clear, but many studies conducted to date indicate that it has a possible 
role in memory consolidation [25]–[27]. 
 
Wake state 
The wake state is characterized by consciousness with consequent activation of muscle 
tone [28]. This is a behavioral active phase with interaction with the external 
environment. From an electrophysiological point of view, during the wake state neurons 
in the cerebral cortex fire irregularly and EEG recordings display low-amplitude, high-
frequency fluctuations. 
 
1.1.2 Sleep functions 
Sleep is a complex and highly regulated behavior that occurs in all the animal species that 
have been studied so far. This suggests that sleep has one or more fundamental functions, 
such as energy conservation [29], body or brain restoration [30], [31], maintaining 
neuronal plasticity [15], [32] and memory consolidation [33]. All these categories imply 
that sleep has a critical role in promoting and maintaining health. Indeed, totally sleep-
deprived rats were dead or sacrificed when death appears imminent within 11-32 days as 
shown by Rechtschaffen [34] meaning a crucial role of sleep in maintain health. 
 
Energy conservation and body restoration 
Since wakefulness accounts for the metabolic active period in the brain, as glycogen 
decreases over the period of wakefulness, the consequent increase of extracellular 
adenosine leads to energy reduction. Thus, it has been suggested that sleep is necessary 
to replenish energy stores in the brain [35] ; sleep may accounts for recovery of energy 
stores and thus restoration of energy balance. Moreover, according to Borbely and 
Achermann [36] delta power during sleep is influenced by this metabolic change. In 
particular, NREM sleep is associated with significant reductions in blood flow and 
metabolism, while total blood flow and metabolism in REM sleep is comparable to 
wakefulness[37]. However, metabolism and blood flow increase in certain brain regions 
during REM sleep, compared to wakefulness, such as the limbic system (which is involved 
with emotions), and visual association areas [38]. Additionally REM sleep requires more 




twitches and penile or clitoral erections [39] are usually observed. Since REM sleep 
requires a metabolic increase, it is expected that other systems will be diminished or 
inhibited to allow the redistribution of energy [22]. For this reason, as described above, 
the REM state is characterized by muscle atonia and loss of thermoregulatory defense 
[40] increasing sensitivity to ambient temperature [41]. All these findings indicate that the 
deterioration of tissue integrity associated with wakefulness is restored during sleep.  
 
Neuronal plasticity 
As the brain is able to change and reorganize its neuronal network it is thought that sleep 
can play a role in neuronal plasticity [42]. Indeed, neuronal plasticity continues 
throughout life even if the nervous system is most plastic in early ontogenetic 
development [43]. The idea that sleep may in some way facilitate synaptic plasticity has 
long been supported by a predominant occurrence of sleep in the human new-born 
occupying two-thirds of the time, with REM sleep occupying half of the total sleep time of 
entire 24-hour period [42]. The percentage of total sleep as well as REM sleep, declines 
rapidly in the early childhood so that by approximately age 10 the adult percentage of 
REM sleep is reached, which is 20% of the total sleep. This evidence clearly indicates that 
sleep and particularly REM sleep in the early stage of life plays an important function in 
promoting nervous system growth and development [42], [44]. Moreover the importance 
of sleep in facilitating neuronal plasticity  has been theorized by the following 
“homeostatic synaptic plasticity” hypothesis [15], [45]–[47]. This hypothesis claims that 
during wakefulness the brain is able to acquire new information, and then tends to be 
saturated at the end of waking time where the synaptic strength is high.  Consequently, 
during the sleep period, the acquired information (accounting for synaptic strength) is 
processed and the strength of each synapse decreases until reaching the baseline level. 
The downscaling of the synaptic strength is driven by SWA, which reinforces connections 
between strongly correlated neurons, while others may be eliminated in order to allow 
the organism to learn afresh the next day. 
Taken together, these findings suggest that sleep may facilitate or even is involved in 
synaptic plasticity. Recent studies have provided evidence showing impaired 
consolidation of learned responses following sleep deprivation [48]. Other studies nicely 




that local plastic changes occur following learning and may be driven by SWA. Indeed, 
they indicate that local SWA homeostasis is strongly correlated with improved 
performance in the task after sleep [3]. 
Memory consolidation 
McGaugh defined  “memory consolidation” as the time dependent process which 
converts labile memory into a more permanent form [33]. In particular this process allows 
the strengthening and consolidation of the information acquired during wakefulness. 
Both sleep stages, non-REM and REM, are involved in memory-related functions, although 
they act on different types of memory. Indeed, non-REM seems to be involved in 
declarative memory (i.e. explicit memory, event explicitly stored and consciously recalled 
or "declared.") [49], [50], while REM sleep is involved in non-declarative memory (i.e. 
memory learned without awareness) [50]. Interestingly, according to the sequential 
hypothesis non-REM operates the first step of the memory process consisting of the 
weakening of non-adaptive memory traces, then the remaining memory traces are stored 
again in a better configuration during the REM [51]. 
Moreover, it has been shown that the duration of REM sleep increases after learning [25] 
and memory formation can be impaired after REM state deprivation [52]. 
 
1.1.3 Hierarchical sleep regulation  
Sleep is a complex behavior that has a hierarchical regulation (see Figure 1). At the basis 
of this regulation, there are the biological and homeostatic control of sleep that 
cooperates with each-other to mateine the sleep-wake cycle. These two processes are 
also regulated by genetic and epigenetic factors. Here are the three classifications of the 
main hierarchical processes of sleep. (see Figure 1): 
- Biological and homeostatic control of sleep; 
- Molecular control of sleep; 
- Genetic and epigenetic control of sleep.   
 
Specifically, in this thesis attention is focused on the epigenetic mechanisms of sleep, 






Biological and homeostatic control of sleep 
Two separate but interacting biological mechanisms play a dominant role in sleep 
regulation: a sleep-dependent process (S Process) and a sleep-independent circadian 
process (C Process) [53].  
 
The S process is a biochemical system that accumulates sleep-inducing substances in the 
brain. Indeed, after a prolonged period of wakefulness it generates the need to sleep, 
reminding the body to sleep. The S process is homeostatically regulated and depended by 
previous wake. This process peaks just before bedtime at night and dissipates throughout 
the night as the need for sleep. This means that a prolonged wakefulness results in more 
intense SWA, which is considered as marker is usually used as a marker of non-REM sleep 
Figure 1 - Hierarchical sleep regulation.  
At the lowest level there is the self-sustained homeostatic control of sleep; in the middle, acting on the 
homeostatic control of sleep, the molecular process (i.e. as the interplay between ox and mch. At the top 























intensity and for sleep pressure [10], [15]. For instance, the longer a subject has been 
awake the higher the spectral power in the slow wave range of the EEG in subsequent 
sleep, which declines during the course of sleep [16]. To date a large body of evidence 
clearly describe that the Process S describes the process of synaptic homeostasis. 
Specifically, the hypothesis claims [15] that, under normal conditions, total synaptic 
strength increases during wakefulness and reaches a maximum just before going to sleep. 
Then, as soon as sleep ensues, total synaptic strength begins to decrease, and reaches a 
baseline level by the time sleep ends. The SWA play a crucial role in this process because 
they are not only considered as an epiphenomenon of the increased synaptic strength but 
have a role to play. The repeated sequences of depolarization—hyperpolarization cause 
the down- scaling of the synapses impinging on each neuron, which means that they all 
decrease in strength proportionally. This means during sleep the strength of each synapse 
would decrease by a proportional amount, until the total amount of synaptic weight 
impinging on each neuron returns to a baseline level. 
Moreover, it has been proposed that SWA is mainly involved in the restorative processes 
of sleep [10], [15], [18]. Indeed, neuroimaging data shows a decrease in absolute levels of 
brain metabolism after sleep that is also consistent with the hypothesis that synaptic 
strength is downscaled during sleep [54]. 
 
The C process conversely reflects how sleep propensity changes over 24-hours, and its 
function is to restrict sleep to a time of day that is ecologically appropriate. Notably, the 
C process is independent of prior sleep-wake history. This process coordinates the light – 
dark cycle of day and night; which controls; sleep timing, feeding patterns, core body 
temperature, brain activity and hormone production over a 24-hour period. The 
oscillatory pattern of circadian activity has a period of approximately 24-hour. In 
mammals, the suprachiasmatic nucleus (SCN) of the hypothalamus is responsible for the 
circadian rhythm which is the main circadian pacemaker. These oscillations are driven by 
the SCN that also co- coordinates the activity of the peripheral clocks of other organs to 
control all biological rhythms within the body [55]. This circadian oscillation is generated 
by a network of clock genes, transcription factors able to regulate other gene expression 




by other time cues such as temperature. Temperature is one of the major signals 
achieving the coordination of all the clocks around the body. Indeed, temperature 
changes can be the results of the influence of the SCN over the sympathetic nervous 
system. However, there isn’t a direct coordination of the peripheral clocks by the master 
clock. Moreover, after SCN lesions sleep is no longer consolidated in one major phase (i.e. 
in rodents during the day, flies and humans during the night), but occurs in short episodes 
throughout the 24-hour period [58]. See Box 1 for further differences between humans 
and rodent’s circadian rhythm. 
 
The sleep-wake cycle is balanced through these two processes. Indeed, experiments on 
human subjects scheduled for a 28-hour rest-activity cycle revealed the uncoupling of the 
sleep-wake cycle from circadian rhythms supporting the two-state model for sleep 
regulation [59]. 
During the sleep period the homeostatic need rapidly dissipates while circadian-regulated 
melatonin is produced. After a prolonged sleep period, usually in the morning, melatonin 
secretion stops, and the circadian alerting system begins. This triggers the body to wake 
up. The homeostatic regulation typically increases throughout the day even if is countered 
and moderated by the C process for arousal, at least until the night when the automatic 















There are some differences in the sleep architecture between humans and rodents. 
Specifically, the sleep-wake cycle is in the opposite phase in rodents compared to 
humans. Indeed, rodents are nocturnal animals, they are awake during the night 
while they sleep during the day. Moreover, human sleep is monophasic, meaning that 
sleep occurs only once during a 24-hour period (usually at night), while rodents’ sleep 
is polyphasic and relatively fragmented [148], [221]. For instance, in humans the non-
REM / REM cycle is repeated from 4 to 6 times per night; these sleep cycles have a 
fairly constant period, with a duration of around 90 minutes [222]. In rodents the non-
REM / REM cycle is shorter lasting around 5 or 12 minutes in mice and rats 





Molecular control of sleep 
Although sleep is regulated by two main processes, the C process and the S process, in 
these processes many neurotransmitters, molecular pathways and different brain 
structures are involved. Specifically, the hypothalamus and brain stem are the main brain 
regions playing a pivotal role in sleep regulation [60]. To date there are four models 
describing the major mechanisms that play a crucial role in the regulation of sleep and its 
transition into wakefulness (See Figure 2 for schematic representation of these models). 
 
The Flip-Flop Model 
The main neuropeptides playing a main role in the transitions between sleep and 
wakefulness are the melanin concentrating hormone (MCH) and orexin/hypocretin (OX) 
(see Box 2 for Physiological roles of Melanin-Concentrating Hormone and Orexin). MCH 
neurons also release Gamma-aminobutyrate (GABA: inhibitory neurotransmitter in the 
brain) and are more active during sleep, in particular during REM sleep [61]. Conversely, 
OX neurons are more active during wakefulness [62], [63]. These two neuropeptides are 
the main constituents of the “Flip-Flop Switch Model” [60] (Figure 2A). According to the 
flip-flop model the balance between the two neuropeptides the OX and MCH model 
enable the transition between sleep and wakefulness avoiding intermediate states. This 
model allows an organism to be clearly awake or asleep with only brief periods spent in 
transition between these states. Since the OX and MCH neuropeptides are located in the 
lateral hypothalamus (LH), it has been thought that the hypothalamus represents the 
regulatory center for the sleep switch. Specifically, the OX neurons are considered to be 
the wake promoters by reinforcing the monoaminergic tone that directly inhibits the 
ventrolateral preoptic nucleus (VLPO), as VLPO neurons do not have any OX receptors. 
Conversely MCH neurons and GABAergic nuclei in the VLPO are more active during sleep 
and inhibit the monoaminergic cell groups as well as OX neurons, further preventing 
monoaminergic activation that might interrupt sleep [60], [64]. Notably, among all models 
that are discussed in this section, we seeking to investigate the role of epigenetics in 







Reciprocal Inhibition Model 
In the brainstem the reciprocal monoaminergic–cholinergic interactions seem to control 
sleep states like non-REM to REM transitions [65]. In this model, named the “Reciprocal 
Inhibition Model”, the brainstem has a different response depending on the occurrence 
of the sleep or wake. This transition between the different sleep stages is given by the 
synchronization and desynchronization of thalamocortical circuits [65], [66]. In this model, 
during wakefulness the serotoninergic (raphe nuclei, RN), adrenergic (locus coeruleus, LC) 
and histaminergic (tuberomammillary nucleus, TMN) neurons are activated, while are 
silenced during non-REM sleep [67] (Figure 2B). During the onset of REM sleep, the 
aminergic and cholinergic neurons are activated while other outputs are inhibited. 
However, cholinergic activity in the brainstem also fire during wakefulness [65]. 
 
Thalamo-cortical loop. 
Thalamocortical processes are oscillatory activity between thalamus and cortical brain 
region. These oscillation act as between different cortical regions of the brain [68]. 
Normal oscillatory activities include slow and fast activities. The fast activities may be 
present in various states of vigilance and frequently coexist with slower rhythms [69].  
There are two main classes of this oscillatory rhythms in the thalamocortical system: 
intrinsic, from a single neuron and extrinsic, from the interaction within a neuronal 
population (e.g. spindle oscillation) [70]. Extrinsic rhythms are typically observed during 
the early stages of sleep. In vivo and in vitro studies suggest that spindle oscillations can 
be generated by the thalamic reticular nucleus although cortical inputs may contribute by 
initiating or amplifying spindle oscillations [71], [72]. This suggests excitatory and 
inhibitory connections between cortical and thalamic reticular cells generating the cortical 
feedback loop. It is this thalamocortical cycle that generates the EEG features from deep 
sleep to high alert [73]. 
 
GABA-Glutamate control of sleep.  
Neurons contain either gamma-amino-butyric acid (GABA) or glutamate are important 
populations of arousal-promoting system [74], [75].  
GABAergic mechanisms in sleep regulation are important. However, due to the 




sleep circuits. Indeed, inhibition by GABA both facilitates and inhibits REM sleep [65]. It 
has been shown that there is a GABA-mediated “switch” between wakefulness and REM 
in the nucleus pontis oralis [76] and there is a direct inhibition of the mesopontine 
cholinergic neurons from GABA in the period right before rapid REM sleep. Glutamate 
increases the activity in mesopontine and pontine reticular in correspondence with the  
onset of REM state [65] (Figure 2D). Moreover, glutamatergic cells of the pons excite 





Figure 2, Sleep models 
A- The flip/flop switch model; OX inhibits VLPO and MCH activity decreases promoting wakefulness; 
During sleep state, VLPO inhibits the monoaminergic cell groups as well as OX while MCH activity 
increases. 
B- The monoaminergic cell groups decrease activity from wakefulness to non-REM state and it is 
almost silent during REM. 
C- The brainstem ascending cortical activation and REM / non-REM transitions. This activity is highly 
correlated with the thalamus activity controlling cortical activation, sleep spindle and EEG 
synchronizations. Hypothalamus is the regulatory center. 
D- GABA-Glutamate control of sleep; inhibition by GABA both facilitates and inhibits REM sleep while 
Glutamatergic cells excite GABA-containing neurons inhibiting somatic motor neurons to produce 
REM sleep atonia. 
BOX 2 
Neurons containing OX or MCH are the main neural population in the lateral 
hypothalamus. These two separate and distinct neuronal population projects to 
similar brain regions.  
Two different neuropeptides are synthetized form OX neurons: orexin A (OXA) and 
orexin B (OXB), which binds two different orexin receptors, the orexin Receptor-1 
(OX1R) and orexin Recepor-2 (OX2R). OXA binds both OX1R and OX2R, while OXB 












































1.1.4 Genetic control of sleep 
A bidirectional relationship between sleep and genetic factors has been described, while 
it has been shown that several mutations affect sleep, it has also been recognized that 
sleep affects the expression of genes.  
The first observation of sleep under genetic control was first  described in a study with 
twins in the 1930’s [77]. This data has also been confirmed by animal studies showing that 
sleep quality and quantity are influenced by genes, observed in more than 70 mutant mice 
lines [78], [79]. Additionally, several human sleep disorders have been identified as having 
a genetic basis.  An example of a human disease that has been linked to a genetic 
alteration of the hypocretin/orexin system is narcolepsy, investigated by performing 
genetic studies in dogs and mice [80]. As given above sleep also influences the expression 
of certain gene. Indeed, whole-genome transcriptomic studies have revealed that the 
brains of sleeping and awake animals also differ at the molecular level. In rats, mice, 
hundreds of brain transcripts change their level of expression between sleep and 
wakefulness [81]. In rats and mice, these changes occur mainly in the cerebral cortex, 
cerebellum and hypothalamus, but can also occur in other areas of the brain. It has been 
observed that sleep-and wakefulness-related transcripts belong to different functional 
The OX physiological functions are expressed in wakefulness stabilization, energy 
expenditure, food reward and addiction behavior and increased food intake. 
Moreover, it has been observed that low glucose levels stimulate OXA release; while 
high glucose levels inhibit OXA release. Furthermore, it has been shown that 
cardiovascular and thermoregulatory regulation are also mediated through OXA, as 
well as it is acting on inflammation, suggesting an anti-inflammatory function in 
neuro-inflammation diseases and it also inhibits apoptosis. 
MCH exerts its action through the MCH1 receptor (Mchr1) and MCH2 receptor 
(Mchr2), although the latter is not functional in rodents. MCH neurons play opposite 
roles in respect of OX in sleep-wake regulation. Indeed, MCH particularly fires during 
REM; MCH activation is regulated by high glucose levels.  
Finally, MCH, as well as OX, are orexigenic peptides, meaning that both are involved 






categories, suggesting that the two behavioral states may favors different cellular 
processes. Overall, it has been observed that neurons are more hyperpolarized during 
sleep than during wakefulness, and mutations/gene alterations can significantly change 
the resting membrane potential, the balance between inhibitory and excitatory 
neurotransmission, and/or the overall neuronal excitability of large sets of neurons which 
are likely to affect the quantity and quality of sleep. 
Additionally, a growing corpus of data indicates that epigenetic mechanisms regulate 
sleep. In particular the role of genomic imprinting, an epigenetic mechanism that 
regulates parent-of-origin effects in mammals and which is involved in the control of sleep 
and in particular of REM sleep is discussed and investigated. 
 
1.2 Epigenetics 
... “the branch of biology which studies the causal interactions between genes and their 
products, which bring the phenotype into being” ...  (Conrad Waddington, 1905-1975) 
 
The term epigenetic means what is beside genetics and is defined as the study of heritable 
changes in gene expression without a change in DNA sequence i.e. changing the 
phenotype without changing the genotype. Epigenetic mechanisms can influence the 
gene expression by switching genes on “active gene" or off “inactive gene" but also 
influence gene activity at the transcriptional and post-transcriptional levels. These 
modifications do not change the DNA sequence but instead they affect how cells "read" 
genes. The main epigenetic mechanisms through which tissue-specific gene-expression 
patterns and global gene silencing are established and maintained are the DNA 
methylation and the histone modifications. 
 
DNA methylation 
DNA methylation is the most frequent modification  in eukaryotic cells and it is known as 
a silencing epigenetic mechanism  [82], [83]. DNA methylation consists of a chemical 
process of adding a methyl group to the carbon at position 5 of the cytosine ring. Since 
DNA methylation is involved in many important biological processes such as X 




DNAs, these patterns must be properly established and maintained. Two components 
regulate the mammalian DNA methylation system: 
- the DNA methyltransferases (DNMTs), with the function of establishing and 
maintain DNA methylation patterns; 
-  the methyl-CpG binding proteins (MBDs), involved in “reading” methylation 
marks. 
 
These DNMTs are essential for embryonic development as demonstrated by Li and Okano 
[84], [85]. The DNMTs can be involved in the recognition of DNA damage, DNA 
recombination and mutation repair [86]. MBDs have a role in the interpretation of the 
methylation signal, through the recruitment of chromatin remodeling protein complexes 
involving histone deacetylases (HDACs), histone methyltransferases (HMTs) and 
chromatin-modifying proteins [87].  
 
Histone modifications 
Histone modification is a covalent post-translational modification of histone proteins. 
Histone modifications occur mostly in the histone amino-terminal tails jutting from the 
nucleosome surface as well as in the globular core region [88]. It has been suggested that 
histone modifications could affect chromosome function through at least two distinct 
mechanisms that have led to the “histone code” hypothesis [89]: 
- the electrostatic charge of the histone may be altered leading to structural change 
in histones or DNA binding; 
- the binding sites for protein recognition modules. 
 
The acetylation of histones usually marks active, transcriptionally competent regions, 
while hypoacetylated histones are found in transcriptionally inactive euchromatic or 
heterochromatic regions. Modifications such as acetylation and phosphorylation, are 
reversible and dynamic, while modifications such as methylation are more stable and are 






1.2.1 Genomic imprinting 
Genomic imprinting is an epigenetic phenomenon that causes genes to be expressed in a 
parent-of-origin-specific manner and as a fundamental concept of genomic imprinting it 
is the core of this thesis.  People inherit two copies of their genes one from the mother 
and the other from the father. Usually both copies of each gene are active, in cells. 
However, in some cases, only one of the two copies are normally active, depending on 
the parent of origin: some genes are normally active only when they are inherited from 
the father; others are active only when inherited from the mother. The methylation 
process (see section 1.2) is the main mechanism of genomic imprinting which enables the 
marking, or “stamping,” of the gene. Notably, the genomic imprinting is a process 
implicated in the development and function of the brain [90].  
To date only a small percentage of all human and mice genes undergo genomic imprinting. 
Approximately 165 and 197 imprinted genes have been identified in humans and mice 
(see supplementary Table 1 for detailed list). These imprinted genes tend to cluster 
together in the same regions of chromosomes. Two major clusters of imprinted genes 
have been identified in humans, one of the short (p) arm of chromosome 11 (at position 
11p15) and another on the long (q) arm of chromosome 15 (in the region 15q11 to 15q13). 
In particular, in this thesis, I focused on investigating the cluster of genes located in 
chromosome 15q11.2-q13, which is responsible for developing the PWS (see Figure 3). 
 
1.2.2 Genomic imprinting defects 
Monoallelic expression of imprinted genes regulated by complex epigenetic mechanisms 
are susceptible to dysregulation at multiple levels. Therefore, defectively imprinted 
regions correlate with several diseases, neurobehavioral and developmental disorders 
resulting from impaired regulation. Single epigenetic alterations can lead to deregulation 
of many genes resulting in the formation of multiple disorders [91]. Parental origin of 
mutations or epigenetic alterations in the gene cluster thus play a critical role in all 
imprinting disorders. 
 
Imprinting and uniparental disomies (UPDs) 
UPDs are the simplest and most frequent type of genetic or epigenetic alterations in 




or part of a chromosome, from one parent and no copies from the other parent. UPD can 
occur as a random event during the formation of egg or sperm cells or may happen in 
early fetal development. In many cases, UPD may have no effect on health or 
development because most genes are not imprinted.  However, should UPD involve 
chromosomes where genes are imprinted, such as chromosome 15 this could/may/will 
lead to several genetic disorders such as either PWS or AS. This thesis focuses only on the 
PWS, as the research laboratory has published several research articles in this field and 
one of the mice models of PWS is currently available in the Italian Institute of Technology 
(IIT). 
 
1.3 Prader-Willi syndrome 
PWS is a neurodevelopmental disorder caused by an imprinting defect. PWS is a rare 
neurologic disease with an estimated prevalence of 1:10,000 – 1:30,000 [92]. PWS is a 
complex genetic multisystem disorder that shows great variability, with changing clinical 
features throughout a patient's life. Based on the extreme variability of the genetic 
background the clinical endophenotypes are greatly mutable between PWS subjects. In 
the following sections the genetic background and the clinical aspect of this syndrome. 
 
1.3.1 Genetic background 
PWS occurs as the result of the absence of expression of paternal genes from 
chromosome 15q11.2-q13. This genetic defect is defined heterogeneously across 
patients; indeed, in the 70 – 75% of cases, PWS is determined by a deletion in the 
paternally derived chromosome 15, while for the remaining 20 – 25% it is caused by 
maternal uniparental disomy. Rarely, PWS can also be caused by a chromosomal 
rearrangement called a translocation, or by a mutation or other defect that abnormally 
inactivates genes on the paternal chromosome 15 [93].  
In the PWS regions there are several paternally expressed protein-coding genes 
implicated; MKRN3, MAGEL2, NDN, NPAP1 and SNURF-SNRPN and a family of paternally 
expressed small nucleolar RNA (snoRNA) genes or clusters. The latter are molecules that 
have a variety of functions, including helping to regulate other types of RNA molecules, 
which play essential roles in producing proteins and in other cell activities, see Figure 3 




is unknown what could be the main candidate genes which play a pivotal role in this 
syndrome. Moreover, the literature is not helpful because several papers are giving 
conflicting results. For instance,  Kanber and colleagues [94] suggest that the MAGEL2 
gene may not be considered as one of the best candidates for PWS, while  Schaaf et al. 
[95] suggest  the opposite.  Nevertheless, recent studies suggest [96] that PWS is 
potentially associated to a disruption of the small nucleolar ribonucleic acid (RNA)-116 
(SNORD116, also called HBII-85) gene. These studies suggest that the loss of a particular 
group of SNORD116 cluster [97], may play a major role in causing the signs and symptoms 
of PWS. In addition, a preclinical study performed in mice carrying the paternal deletion 
of the Snord116 shows that the paternal imprinted gene plays a crucial role in developing 
the major endophenotypes of this syndrome. Indeed, this animal model reproduces 
hyperphagia and sleep-wake alterations observed in PWS patients [98]–[100]. These 
findings suggest that SNORD116 may play a crucial role in PWS and it could be considerate 
as a potential target for new intervention. However, not all aspects of the PWS phenotype 
have been reproduces with deletions of Snord116. Indeed, the hypothalamic congenital 
deletions of this gene don’t lead to hyperphagia and obesity, while adult-onset deletion 
of Snord116 in the hypothalamus leads to hyperphagia suggesting an important role of 
this gene in the regulation of metabolism not only during the development but also during 
the life spam.  
However, it not completely understood how a missing SNORD116 cluster could contribute 
to the main features of the disorder. This Ph.D. attempts to fill this gap in the literature 
by investigating the role of this gene in the PWS. In particular focusing on the sleep 
alteration that characterizes this syndrome and which significantly compromises the 
quality of life of PWS patients. To specifically investigate the role of the SNORD116 cluster 
in the PWS as well as in the regulation of sleep, a mice model having the paternal deletion 
of the Sonord116 gene was used. Notably, the PWS region is extremally conserved 





1.3.2 Clinical features  
The clinical picture and the nutritional stages have been classically described as having 
two phases along their life [101]: 
i. Phase I, also named as the infancy stage, where newborns are characterized by 
profound hypotonia which can lead to asphyxia, feeding difficulties, including a 
poor suck, which may lead to failure to thrive. 
ii. Phase II, starting from 2 to 8 years which is characterized by “hyperphagia leading 
to obesity” [101]. Thus, if obesity is not  well controlled it can lead to other related 
problems such as cardiovascular problems, hypertension, diabetes mellitus, 
thrombophlebitis, chronic leg edema and respiratory infections [92]. The literature 
suggests that there is a “switch” between poor feeding and hyperphagia that 
occurs at approximately 18–36 months in individuals with PWS [102]–[105]. 
 
Additionally, PWS patients also have behavioral problems and cognitive impairment, that 
may be explained by a lower cortical complexity observed in MRI studies [106]. 
 
1.3.3 Sleep alterations and PWS 
One of the typical features of PWS is the sleep alterations affecting approximately 76% of 
PWS patients [8], [97].  It has been shown that 90–100% [107] of adults with PWS  have 
excessive daytime sleepiness (EDS) [108] with reduced sleep onset latencies both at 










































Figure 3 PWS Cluster 
Representation of the genetic and expression map of chromosome region 15q11.2-q13. PWS region has 
five paternal-only expressed unique-copy genes that encode polypeptides (MKRN3, MAGEL2, NDN, and 




studies have reported a complete absence or dysregulation of sleep spindles in PWS 
patients [109], [110]. One of the predominating endophenotypes of PWS is obesity. 
Indeed these are several bodies of evidence suggesting that there is a strong relationship 
between sleep and metabolic disorders [111], [112], suggesting the sleep alteration in the 
PWS may also exacerbate the metabolic features. Evidence supporting a positive 
relationship between EDS and body mass index (BMI) has been also described in patients 
with PWS [108]. Breathing disturbances during sleep, including sleep apnea, may be 
exacerbated by obesity in individuals with PWS [113], [114]. Additionally, EDS could also 
be attributed to the level of cerebrospinal fluid (CSF) hypocretin, which was found to be 
lower than normal in four patients with PWS and the levels correlated with the severity 
of EDS [115].  Dauvilliers et al. [116] found that one patient with Kleine–Levin syndrome 
(also affected by PWS) had a two-fold decrease in hypocretin-1 level only during the 
symptomatic episode, suggesting a possible intermittent alteration of the hypocretin 
system. 
Moreover, sleep disturbances include REM alteration such as a reduction of the REM 
latency and an increase in the number of REM periods [109]. It has been also shown that 
PWS patients have altered sleep architecture manifested by a non-REM sleep instability 
[117]. In some clinical studies PWS patients presented narcoleptic-like symptoms, an EEG 
profile characterized by the intrusion of REM sleep into the transition between 
wakefulness and sleep, cataplexy or a transient loss of muscle tone [92], [118].  
 
1.3.4 Hypothalamus and PWS  
Hypothalamic dysfunction could be responsible for some of the clinical features of the 
PWS such as disturbance of energy regulation, temperature instability, short stature, 
hypogonadism [119], [120], abnormal ventilatory control and in the pathogenesis of EDS 
[108]. Indeed, the hypothalamus is one of the regions of the brain which plays a crucial 
role in the control of the sleep-wake cycle and in the regulation of many functions 
throughout the body, such as feeding, metabolism and temperature, all of which are 
significantly compromised in PWS. 
In supporting the fact that PWS may be linked to hypothalamic insufficiency there is a 
paper [121] reporting hypothalamic pathology and dysmorphism in postmortem studies 




Moreover, the PWS patients have more sleep cycles per night and more REM periods that 
have been shown to be controlled by the hypothalamus. Hypothalamic dysfunction in the 
PWS can also be related to respiratory alterations through obesity, linked with 
hyperghrelinemia, and hypercapnia suggesting the sleep alteration in the PWS may also 
exacerbate the metabolic features [122]–[124]. Additionally, it has been shown that some 
of the paternally imprinted genes (i.e. Megel2 and Snord116) playing a crucial role in the 
pathophysiology of PWS are highly expressed in the hypothalamic region. Notably, it has 
been shown in an embryonic chimeric experiment [125] that paternally imprinted genes 
are extremely important for hypothalamic formation.  
 
1.3.5 Current treatment 
Currently, there is no cure for PWS, however, many treatments may allow for better 
outcomes, especially when provided early. As a main treatment for sleep alterations the 
first intervention is to improve sleep hygiene by shaping behavior to assure the 
appropriate amount of sleep and to supplement this with planned naps, if necessary. The 
second intervention is to treat the source of sleep disruption by using non-invasive 
intermittent positive pressure ventilation (NIPPV), CPAP, tonsillectomy and 
adenoidectomy as in the general population. Then, the daytime use of stimulant 
medication (either methylphenidate or dextroamphetamine derivatives) and/or modafinil 
(Provigil) is recommended. Modafinil is approved for the treatment of narcolepsy and 
EDS. Modafinil has been shown to be a safe and effective treatment for EDS and 
narcolepsy-like phenotype in PWS patients [126]. However, this drug has many side 
effects, including headaches, anxiety, trouble sleeping, nausea and hallucinations. 
Currently an alternative to Modafinil is Pitolisantan orally active antagonist/inverse 
agonist of the human histamine H3 receptor. It works by enhancing the histaminergic 
transmissions in the brain, acetylcholine release in the prefrontal cortex and hippocampus 
and dopamine release in the prefrontal cortex but not in the striatum. Pitolisant as well 
as Modafinil is used to enhance wakefulness in patients with EDS and a variety of 
comorbid neurological diseases: narcolepsy [127], Parkinson’s disease and obstructive 
sleep apnea [128], [129]. However, the use of Pitolisant with PWS patients is under 
consideration by the scientific community. For this reason, in this thesis, pre-clinical data 











Aims of the studies 
 
Prader-Willi (PWS) is a neurodevelopmental disorder caused by a genomic imprinting 
defect. In particular, the defect involves the cluster of the paternally imprinted genes 
located in the chromosome 15 (15q11-13, Figure 3, Chapter 1). Paternally imprinted genes 
are extremely important for hypothalamic formation as well as for sleep-wake cycle 
regulation. Among all genes located in the PWS locus, the Snord116 gene is the main 
candidate for developing the major endophenotypes of PWS. Snord116 is also highly 
expressed in the hypothalamus, which is one of the brain regions involved in sleep 
regulation. In particular, animal studies suggest that this gene may be involved in the sleep 
alterations of this syndrome rather than the metabolic alterations. However, it is unclear 
if Snord116 plays a role in the hypothalamic function and formation as well as the 
biological and homeostatic control of sleep. 
Based on the above evidences the three aims of this thesis are: 
I. Study I to investigate whether Snord116 may play a role in the hypothalamic 
formation and in the regulation of the biological and homeostatic control of sleep. 
II. Study II to investigate the role of Snord116 in the regulation of macrostructural 
sleep aspects and in the bran-circuits involved such as the thalamic reticular 
nucleus (TRN)/ thalamus circuits or in corticothalamic afferents. 
III. Study III to investigate a new alternative pharmacological approach for PWS aimed 
at ameliorating the sleep disturbances that significantly comprise the quality of life 
of these patients by using Pitolisant in mice carrying the deletion of the Snord116 
gene. 
 
Notably, most of the data collected in these three studies was analyzed by using Phenopy, 
a practical user interface for the management of behavioral and sleep analysis developed 





2.1 Study I 
Snord116 may play a role in the hypothalamic formation and in the regulation of the 
biological and homeostatic control of sleep 
 
Imprinted genes are highly expressed in the hypothalamus; however, whether specific 
imprinted genes affect hypothalamic neuromodulators and their functions is unknown. It 
has been suggested PWS, a neurodevelopmental disorder caused by lack of paternal 
expression at chromosome 15q11-q13, is characterised by hypothalamic insufficiency. 
Here, we investigated the role of the paternally expressed Snord116 gene within the 
context of sleep and metabolic abnormalities of PWS, and we reported a novel role of this 
imprinted gene in the function and organisation of the two main neuromodulatory 
systems of the lateral hypothalamus (LH), namely, the orexin (OX) and melanin 
concentrating hormone (MCH) systems. We observed that the dynamics between 
neuronal discharge in the LH and the sleep-wake states of mice with paternal deletion of 
Snord116 (PWScrm+/p-) are compromised. This abnormal state-dependent neuronal 
activity is paralleled by a significant reduction in OX neurons in the LH of mutants. 
Therefore, I proposed that an imbalance between OX- and MCH-expressing neurons in 
the LH of mutants reflects a series of deficits manifested in the PWS, such as dysregulation 
of rapid eye movement (REM) sleep, food intake and temperature control. 
 
2.2 Study II 
Snord116 in the regulation of the sleep macrostructural aspect and in the brain-circuits 
 
In the study I, we observed that PWScrm+/p- mice are characterized by REM sleep 
abnormalities. In this study, we investigated the macrostructural aspect of sleep such as 
REM sleep features and sleep spindles within non-REM graphoelements sleep. While the 
former is thought to contribute to neuronal network formation early in brain 
development, the latter are markers of thalamocortical processes. Both signals are often 
compromised in neurodevelopmental disorders and influence functional properties of 
cortical neurons. Thus, we isolated and characterized the intrinsic activity of cortical 
neurons using in vitro microelectrode array (MEA) studies. Regarding the MEA 




be shown. For further information refer to the paper of which I am the first author (sharing 
authorship) at the following link: https://doi.org/10.1101/809822. 
These results indicate that the Snord116 gene in mice selectively influences REM sleep 
properties, such as theta rhythms and the organization of REM episodes throughout 
sleep-wake cycles. Moreover, sleep spindles present specific abnormalities in PWS model 
systems, indicating that these features of sleep may translate as potential biomarkers in 
human PWS. We observed abnormalities in the synchronization of cortical neuronal 
activity that are accounted for high levels of norepinephrine. 
In conclusion, these results provide support for an important role of Snord116 in 
regulating brain activity during sleep and, in particular, cortical neuronal properties, 
thereby opening new avenues for developing interventions in PWS. 
 
2.3 Study III 
New alternative pharmacological approach for PWS 
 
In the Study I and II, we observed that PWS is related to hypothalamic insufficiencies 
showing also a reduction of orexin neurons. Additionally, they have also sleep-wake cycle 
alteration, disrupted REM sleep, and temperature instability. The purpose of this study 
was to investigate the response of PWScrm+/p- mice to acute administration of Pitolisant 
aimed at improving sleep phenotypes. Pitolisant enhances wakefulness bypassing the 
orexin system and acting directly on the histamine system. The result of this study 
confirmed again that PWScrm+/p- mice have an alteration in the macrostructure of sleep 
affecting only REM sleep, without substantially disrupting any other sleep stages. 
However, PWScrm+/p- mice exhibited a high propensity to sleep, an inability to maintain 
wakefulness.  
These findings indicate that Pitolisant ameliorates the REM sleep alteration in these mice. 
However, other studies are needed to investigate whether Pitolisant may also modulate 






Materials and methods 
 
In the following section are described the animal models and methods used for each 
study. 
 
3.1 Study I 
Animal husbandry, breeding, and genotyping 
All animals were housed in controlled temperature conditions (22 ± 1 °C) under a 12-hour 
light/dark cycle (light on 08:00–20:00), with libitum access to food (standard chow diet) 
and water unless otherwise required by the experimental procedure. 
Experiments were performed using adult mice at 15-17 weeks with paternal deletion of 
the Snord116 gene and IPW exons A1/A2 B [97] (PWScrm+/p-) and their wild-type 
littermates as control mice (PWScrm+/p+). To maintain the colony, mice were bred and kept 
through paternal inheritance on a C57BL/6J background. Genotyping was performed as 
previously described [100]. Briefly, PCR analysis of genomic DNA from ear punches was 
performed using the primer pair PWScrF1/PWScrR2 (5’-AGAATCGCTTGAACCCAGGA and 
5’-GAGAAGCCCTGTAACATGTCA, respectively). The deletion of PWScr resulted in a PCR 
product of approximately 300 bp, which was absent in the wild-type genotype. 
For experiments in narcoleptic mice, 3 age-matched groups of male and female congenic 
mice from two different strains (≥ 9 generations of backcrossing) on the C57Bl/6J genetic 
background were used, as follows: 
I. mice with congenital deficiency of OX gene (Ppox) knockout (KO) [130] (n=11); 
II. mice hemizygous for a transgene (ataxin-3 [Atx] mice), the targeted expression of 
which causes selective ablation of OX neurons [131] (n=4); 
III. wild-type controls (n= 4). Mouse colonies were maintained in the facilities of the 
Department of Biomedical and NeuroMotor Sciences at the University of 
Bologna, Italy.  
 
Mice were housed under a 12-hour light/dark cycle at an ambient temperature of 25°C 




All animal procedures were approved by the Animal Research Committee and the 
Veterinary Office of Italy for Istituto Italiano di Tecnologia (IIT) Genova. All efforts were 
made to minimize the number of animals used and any pain and discomfort according to 
the principles of the 3Rs [132]. 
 
Experimental approach 
Neuronal activity in the mouse LH is time-locked with different behavioral and 
physiological states of the brain. 
To identify neuronal populations in the LH that control different physiological behaviors, 
we adopted a combined experimental approach (Figure 4A) in which I monitored single 
unit activity (SUA) at the LH in parallel with the cortical state of each animal by means of 
electroencephalogram and electromyogram (EEG/EMG) recordings. The EEG/EMG 
information allows the identification of wakefulness, REM sleep and non-REM sleep states 
in the animal, which represent the three main behavioral states of the mammalian brain. 
Mice were kept throughout a regular sleep-wake cycle, and EEG/EMG/SUA were recorded 
during the light-to-dark transition (baseline 1, B1) and during the dark-to-light transition 
(baseline 2, B2) to test the neuronal responses during the minimum and maximum levels 
of sleep pressure, respectively (Figure 4B upper panel). Then, each mouse underwent 
sleep deprivation (SD) to test the homeostatic response following sleep loss (Figure 4B 
middle panel). A total of 569 well-sorted units were successfully recorded from PWScrm+/p+ 
wild-type mice, and 548 units were recorded from PWScrm+/p- mutant mice across all time 
points. 
Based on the distribution of the firing activity of each unit, we were able to distinguish 
populations of putative neurons in the LH that were time-locked with the occurrence of 
specific sleep-wake states (Figures 4C and 4E). In particular, we identified neurons (Figure 
4E) associated with sleep (S-max) or wakefulness (W-max). However, we distinguished 
between non-REM (NR-max), REM (R-max) neurons and neurons firing in both stages 
(NRR-max) (see supplementary Table 2). We also identified a group of neurons that did 
not show significant changes in their firing rate across the sleep-wake states, and we 
called this latter class of neurons “ws” (wake and sleep). 
Moreover, to test the other fundamental function of LH, feeding, we food deprived each 




made available, we evaluated the neuronal responses to food intake (Figure 4B lower 
panel). In this experiment, a total of 147 units were identified from PWScrm+/p+ mice and 
74 units from the PWScrm+/p- mice in response to food deprivation. 
Following the food deprivation protocol, we also distinguished three different classes of 
neurons in the LH that respond to food intake. In particular, we defined type I and II 
neurons as those that fire maximally after or before nose-poking/feeding activity, 
respectively (Figures 4D and 4F). In this experiment, a third class of neurons, type III 
neurons, was defined as non-responding neurons. 
 
Experimental protocols 
LH neuronal activity recordings. To investigate the neuronal dynamics of the lateral 
hypothalamus (LH), EEG/EMG and SUA were simultaneously recorded in eight male adult 
PWScrm+/p- and PWScrm+/p+ mice. Animals were individually housed after surgery in their 
home cages with a food hopper (a hole with an infrared beam) connected to a food 
dispenser that automatically delivers food pellets after a nose poke (powered by AM-
Microsystems [133]. The food used was 20 mg dustless precision pellets (Bioserv). After a 
7-day recovery period after surgery, each mouse was connected to a flexible cable and 
swivel that allowed free movement within the cages; the mice were habituated for 2 days 
to the cable before SUA and EEG/EMG recordings (Figure 4A). Recordings of EEG/EMG 
with SUA were acquired at two different baseline (BL) time points (B1 and B2; Figure 4A) 
for 2-hour according to the C Process and S Process of sleep. Next, to investigate sleep 
homeostasis, SUA and EEG/EMG were recorded during the first hour of the rebound 
period (RB, Figure 4A) following 6-hour of total sleep deprivation (SD) and at other two 
time points over the 18-hour recovery period (SD1 and SD2, Figure 4A). 
After a restoration period of 5 days from the previous SD, animals were fasted for 12-hour 
during the dark period, which corresponds to the active phase of mice. At the beginning 
of the light period, mice were fed. A few food pellets were initially provided to encourage 
the mice to eat, and thereafter, food pellets were provided only after nose-poke activity. 
SUA was continuously recorded for 2-hour after being fed (Figure 4A). EEG/EMG was not 






Homeostatic investigation of sleep.  
To investigate the role of the Snord116 gene in the regulation of the homeostatic 
component of sleep, we recorded EEG/EMG in ten male adult PWScrm+/p- and PWScrm+/p+ 
mice over 24-hour of baseline (BL) at 22 ± 1°C. The BL recordings began at ZT 0 (the time 
of light onset in the 12-hour light/dark cycle), and then, mice were sleep deprived during 
the first 6-hour of the light phase (ZT 0–6) by gentle handling (introduction of novel 
objects into the cage, tapping on the cage, and, when necessary, delicately touching) and 
then allowed 18-hour of recovery (ZT 6–24, RB). 
 
Investigation of REM sleep propensity.  
To investigate the REM sleep propensity, we housed male adult PWScrm+/p- and PWScrm+/p+ 
mice for five weeks at 30 ± 1°C, which is close to or within the thermoneutral zone (TNZ) 
of mice [134], [135]. Then, these mice underwent continuous recordings for 24-hour at 
30°C ambient temperature while undisturbed and freely moving in their cages.  
 
Surgery 
Mice were anaesthetized using 1.5%–2.5% isoflurane in oxygen and placed in a stereotaxic 
frame (David Kopf Instruments, Tujunga, CA). To assess the sleep-wake cycle, mice were 
surgically implanted with a telemetric transmitter (volume, 1.9 cm 3; total weight, 3.9 g; 
TL11M2-F20-EET; DSI, St. Paul, MN, USA) connected to electrodes for continuous 
EEG/EMG recordings. A wireless EEG transmitter/receiver, which also contained a sensor 
to detect body temperature, was subcutaneously implanted. Specifically, EEG wire 
electrodes were implanted into the frontal cortex (coordinates: 2 mm posterior to the 
bregma and 2 mm lateral to the midline in the right parietal skull) and the parietal cortex 
(coordinates: 3 mm anterior to the lambda and 2 mm lateral to the midline in the right 
frontal skull). EMG was recorded by two stainless steel wires inserted bilaterally into the 
neck muscles. Subsequently, to record SUA, a tetrode-based 16-channel micro-wire array 
(4 x 4, 5.3 mm, 100-200-1250) of silicon probes (NeuroNexus Technologies) was implanted 
into the LH (coordinates relative to the bregma: –1.45 mm anteroposterior, –1.0 mm 
mediolateral, and –4.8 mm dorsoventral) of the contralateral hemisphere with respect to 
the EEG electrodes (Figure 4A). Mice were operated on by performing a small craniotomy, 




mm diameter) were used to anchor the implant. One screw placed in the cerebellum was 
wrapped by the electrode ground. Next, the tetrode and the ground wire were covered 
with dental acrylic. Following surgery, all animals were administered paracetamol (200 




At the end of the last recording session, animals were sacrificed, and the locations of the 
recording electrodes were verified histologically. Mice were anaesthetised using 
pentobarbital anaesthesia (100 mgr/kg, i.p.), and microlesions were made at the tip of 
one or two microwires by passing a small current (5 m A, 10 s). The animals were 
transcardially perfused with 10 ml of phosphate-buffered saline (PBS) before infusion of 
4% paraformaldehyde (PFA) in PBS. The brains were removed and equilibrated in 30% 
sucrose, sectioned at 40 µm on a freezing microtome, mounted onto gelatin-coated slides, 
air dried, dehydrated in ethanol, stained with Nissl substance, cleared with xylene, and 
cover slipped with DPX (Figure 4A). Three mice were excluded from the study because the 
electrode was not correctly placed in the LH (Figure 4A). 
 
Thermal imaging 
Surface body temperature was continuously recorded in PWScrm+/p- and PWScrm+/p+ mice 
for 24-hour at 22°C and 30°C using an infrared thermocamera (FLIR A20). The 
thermocamera was positioned above the cage where the mice were individually housed. 
Head (T-head) and tail temperatures (T-tail) were obtained by manually analyzing the 
recorded video (1 frame/s) using a dedicated software program (Thermocam Research, 
FLIR). T-head was used to compute the heat loss index (HLI). HLI was calculated by the 
equation (T-head - Ta)/(T-tail - Ta) [136]. T-head, T-tail and HLI values were collapsed into 
2-hour bins and compared between conditions in the two experimental groups. 
Additionally, body weight was measured weekly in small groups of both PWScrm+/p- and 
PWScrm+/p+ mice for 5 weeks at 22°C and at the TNZ (n= 10); the first body weight 
measurement was recorded at 15 weeks of age. Another group of animals (n=10) born 





A two-way ANOVA with repeated measures on both factors (group x time) was used for 
the statistical analysis of T-head, T-tail, and HLI over the conditions investigated between 
the two genotypes (+/+ vs. -/-). A two-way ANOVA was employed for the statistical 
analysis of body weight (group x time). These data were scored in preliminary analysis by 
Matteo Cerri from the Dipartimento di Scienze Biomediche e Neuromotorie at University 
of Bologna. 
 
Real-time quantitative PCR 
Thirty PWScrm+/p- and PWScrm+/p+ mice were sacrificed by cervical dislocation at three 
different time points: at ZT 6 (T0), immediately after 6-hour of total SD (T1), and 1-hour 
after previous SD (ZT 7; T2). Total RNA was extracted from the hypothalamus by the Trizol 
method (Sigma-Aldrich) according to the manufacturer’s instructions [137]. RNA 
concentrations were then determined by a NanoDrop 2000c spectrophotometer. The 
complementary DNA was obtained from up to 2 mg of total RNA by using a high-capacity 
RNA-to-cDNA kit (Invitrogen) and then analyzed with SYBR GREEN qPCR mix. Reactions 
were performed in three technical replicates using an AB 7900HT fast real-time PCR 
system (Applied Biosystems). The relative expression levels were quantified according to 
the previously described ΔΔCT calculation method [138]. Gapdh was used as a reference 
gene. The specific primer pairs used for the analysis were designed using Primer3 (see 
supplementary Tables 4). An unpaired t-test was used to compare the differences 
between the genes investigated in the two genotypes. 
Narcoleptic mice were sacrificed between ZT 6 and ZT 7, and the hypothalamus and cortex 
of the brain were dissected and immediately frozen. 
The experiment and the analysis of this part were done in collaboration with my 
colleagues (Marta Pace and Andrea Freschi) of the Genetics and Epigenetics of Behaviour 
(GEB). 
 
Perfusion and immunohistochemistry (IHC) 
PWScrm+/p- and PWScrm+/p+ mice were transcardially perfused with 10 ml of PBS before 
infusion of 4% PFA in PBS. Perfused brains were postfixed for 24-hour in 4% PFA at 4°C 
before immersion in 30% sucrose. To quantify lateral hypothalamic neurons expressing 




brain regions within–1.10/–1.90 mm of the bregma. Before IHC staining, the sections were 
washed three times with PBS for 10 min each and then blocked in 5% of the appropriate 
serum (normal goat serum or normal donkey serum) in 0.1% Triton X-100 in PBS for 1-
hour. The sections were incubated with rabbit PPOX polyclonal (1:20; Millipore) and pro-
melanin-concentrating hormone (PMCH; 1:50; Invitrogen) primary antibodies in 1% 
serum in 1% Triton X-100/PBS at room temperature overnight. The sections were then 
washed three times in PBS for 5 min each. They were incubated with appropriate 
secondary antibodies (1:1000) (goat anti-rabbit IgG, Alexa Fluor 488) in 1% serum in 1% 
Triton X-100/PBS for 2-hour at room temperature in the dark, washed three times in PBS 
for 5 min each, and counterstained with Hoechst (1:400 in PBS; Sigma-Aldrich). Finally, 
the sections were washed in PBS and mounted on glass slides using ProLong gold antifade 
reagent (Invitrogen). The sections were imaged with an upright Widefield Epifluorescence 
Olympus BX51 microscope equipped with a 4x UPLFLN N.A objective. The microscope was 
controlled by Neurolucida software. 
The percentage of OX- and MCH-positive cells was manually scored using NIH ImageJ 
software. A total of 3-5 sections were evaluated for each mouse (n= 4 for genotype), and 
the neuron counts were normalized to the total number of DAPI-stained nuclei 
(approximately 300 nuclei per microscopic field). All digital images were processed in the 
same way between experimental conditions to avoid artificial manipulation between 
different data sets. An unpaired t-test was used to compare differences between the two 
genotypes. The experiment and the analysis of this part were done in collaboration with 
my colleagues (Marta Pace and Andrea Freschi) of the Genetics and Epigenetics of 
Behaviour (GEB). 
 
Chromatin immunoprecipitation (ChIP) 
For the analysis of PEG3 binding, H3K4me2/3 and H3K27me3, ChIP was performed on 
formaldehyde cross-linked chromatin isolated from the hypothalamus of 28 PWScrm+/p- 
and PWScrm+/p+ mice. Briefly, the tissue of seven different hypothalamic was minced. 
Formaldehyde was added to the tissue, which was resuspended in PBS at a final 
concentration of 1% and incubated at room temperature for 15 min while shaking. The 
reaction was stopped by the addition of glycine to a final concentration of 0.125 M. The 




(50 mM HEPES pH 8, 10 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton 
X-100) for 90 min at 4°C. Isolated nuclei were lysed in lysis buffer 2 (10 mM Tris–HCl pH 
8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM EGTA) for 60 min at 4°C. The chromatin was 
sheared in sonication buffer (10 mM Tris–HCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 0.1% sodium deoxycholate and 0.5% N-lauroylsarcosine) to an average size of 100–
400 bp using the Sonifier 150 (Branson). 
For each IP, 100 μg of sonicated chromatin was diluted in a final volume of 600 μl with 
sonication buffer and pre-cleared with 30 μl protein A/G agarose beads (Santa Cruz) for 
4-hour at 4°C on a rotating wheel. Anti-PEG3 antibody (7 μg, Abcam Ab99252), anti-
histone H3K4me3 (7 μg, Abcam Ab8895), and anti_Histone H3K27me3 (7 μg, Abcam 
Ab195477) or rabbit IgG were added to the pre-cleared chromatin and incubated 
overnight at 4°C on a rotating wheel. Chromatin was precipitated with 30 μl protein A/G 
agarose beads for 4-hour at 4°C with rotation. The beads were then washed five times 
with 500 μl RIPA buffer (10 mM Tris–HCl pH 8.0, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 
0.1% sodium deoxycholate, 1% Triton X-100 and 0.1% SDS) and once with each of the 
following buffers: WASH buffer (50 mM HEPES, 0.5% sodium deoxycholate, 1% Triton X-
100, 1 mM EDTA, 500 mM NaCl and 0.2% NaN3), LiCl buffer (0.25 M LiCl, 0.5% NP-40, 0.5% 
sodium deoxycholate, 1 mM EDTA and 10 mM Tris pH 8) and TE buffer (10 mM Tris pH 8, 
1 mM EDTA). The bound chromatin was eluted in 100 μl TE buffer. Crosslinks were 
reversed by incubation with O/N at 65°C after the addition of 1 μl RNAse cocktail (Ambion) 
and 2 h at 50°C after the addition of 2.5 μl SDS 20% + 2.5 μl 20 mg/ml proteinase K (Sigma). 
DNA was extracted by using a QIAquick Gel Extraction Kit (Qiagen). Immunoprecipitated 
or 1% input DNAs were analyzed by real-time PCR using SYBRGreen PCR Master Mix (Bio-
Rad) on a 7900HT Fast Real-Time PCR System (Applied Biosystems). Each reaction was 
performed in triplicate, and experiments were performed twice. The specific primer pairs 
used for the analysis were designed using Primer3 (see supplementary Table 3). An 
unpaired t-test was used to compare differences between the two genotypes. 
The experiment and the analysis of this part were done in collaboration with my 







Hypothalamic cell culture transfected with Snord116-siRNA 
Embryonic rat hypothalamus cell line R7 (rHypoE-7 – Tebu-bio) cells were cultured in 
Dulbecco's modified Eagle's medium (Sigma Co. Ltd, St Louis, MO, USA) supplemented 
with 10% foetal bovine serum, 50 units of penicillin and 50 μg/ml of streptomycin at 37°C 
under an atmosphere of 5% CO2. Cells were seeded in six-well plates (Nunc Co., Roskilde, 
Denmark) at a density of 1 × 105 cells per well. The day after cell seeding, 20 μM of 
Silencer® Snord116-siRNA (Ambion®) was mixed with RNAiMAX Lipofectamine (Life 
Technologies) reagent, and the mixture was added to each dish. We used MISSION® siRNA 
universal negative control #1 (Sigma) as a negative control at 20 μM. Cells were incubated 
for 48-hour after transfection, and RNA was extracted by using the Trizol method for gene 
expression analysis (see supplementary Table 3). Experiments were conducted in 
triplicate. An unpaired t-test was used to compare differences between the two 
genotypes. 
The experiment and the analysis of this part were done in collaboration with my 
colleagues (Marta Pace and Andrea Freschi) of the Genetics and Epigenetics of Behaviour 
(GEB). 
 
RNA sequencing and analysis 
Total RNA was homogenized in Trizol Reagent (Sigma-Aldrich). Libraries were prepared 
using a TruSeq polyA mRNA kit (Illumina) according to the manufacturer’s instructions and 
sequenced by using the NovaSeq 6000 System (Illumina).  
Raw sequence reads were quality controlled through FASTQC 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and trimmed using 
Trimmomatic (v0.38) (http://www.ncbi.nlm.nih.gov/pubmed/24695404). To quantify the 
transcript abundances, we used Kallisto (v0.44.0) [139]. Kallisto was also used to build an 
index from the mouse reference genome (EnsDb.Mmusculus.v79) with default 
parameters. To import and summarize transcript-level abundance of Kallisto, the R 
package Tximport was used. Differential expression was assessed using DSeq2 [140]. 
Adjusted p-values less than 0.05 were selected, and only genes with > 2-fold change were 
considered in the analyses. 
GO analysis was performed using Metascape [141] http://metascape.org/). The identified 




The analysis of this part was done in collaboration with Alfonso Urbanucci from the 
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, 
Oslo Norway and Marta Pace from the Genetics and Epigenetics of Behaviour (GEB). 
 
Electrophysiological data analysis 
Cortical EEG/EMG signals were recorded using Dataquest A.R.T. (Data Science 
International). Signals were digitized at a sampling rate of 500 Hz with a filter cut-off of 50 
Hz. EEG signals were filtered at 0.3 Hz (low-pass filter) and 0.1 KHz (high-pass filter). The 
polysomnographic recordings were visually scored offline using SleepSign software (Kissei 
Comtec Co. Ltd, Japan) per four second epoch window to identify wakefulness (W), non-
REM or REM sleep stages, as previously described [138], [142]. Scoring was performed by 
a single observer who was blinded to the mouse groups. 
Specifically, W, non-REM and REM states were scored when characteristic EEG/EMG 
activity occupied 75% of the epochs. EEG epochs determined to have artefact 
(interference caused by scratching, movement, eating, or drinking) were excluded from 
the analysis. Artefact comprised <5-8% of all recordings used for analysis. 
The percentage of time spent in total sleep, non-REM and REM sleep out of the total 
recording time was determined. The amount of time spent in each stage was established 
by counting the types of epochs (W or NR or R) and averaging over 2-hour periods. The 
spectral characteristics of the EEG were further analyzed. The EEG power densities of the 
delta (0, 5–4 Hz) and theta (5–9 Hz) frequencies in non-REM and REM sleep were 
computed for all conditions investigated. To exclude variability due to the implantation, 
the power density of each animal was normalized to the power density of the last 4-hour 
of the light period of the 24-hour recording (22°C and 30°C, respectively). The 
temperature was recorded at a sampling rate of 5 Hz within the range of 34°C – 41°C and 
averaged over 2-hour periods. A two-way ANOVA with repeated measures (factors of 
group x time) was used for the statistical analysis of the 2-hour averaged time-course 
changes in the percentage of each sleep stage (W, non-REM and REM sleep), delta power, 
theta power and body temperature between the two genotypes (+/+ vs. -/-). The 
statistical analysis of the cumulative amount of W, non-REM, and REM sleep over the dark 
and light periods among the groups at BL, after SD and at the TNZ was performed with 




and in the delta and theta power during the first 4-hour of rebound after SD between the 
two genotypes. 
SUA data acquisition was performed using an RX7 system (Tucker Davis Technology, TDT). 
The synchronization between the behavioral set up and the TDT system was guaranteed 
with transistor-transistor logic (TTL) from the CHORA feeders to the TDT system. The data 
were digitally sampled at 12 kHz. To detect spike timestamps, the neural traces were 
filtered with a bandpass filter (300 – 5000 Hz), and then, the common average reference 
(CAR) was applied [143]. Spikes were detected using a hard threshold that was computed 
as previously described [144]. A correlation filter was applied between each detected 
spike and the corresponding signal chunk in the other recording sites to detect and 
exclude false positive spikes given by movement artefact. 
To specifically identify active neurons in the LH, we imposed two criteria: (i) the refractory 
period following a spike was set to 1 ms; and (ii) the maximum duration of a waveform 
was set to 5 ms. Spikes of individual neurons were sorted offline using the noise robust 
LDA-GMM algorithm based on a linear discriminant analysis [145]. To identify neurons 
that specifically respond to a particular sleep-wake cycle, the unit activity was 
subsequently analyzed per 4-s epoch in each sleep-wake stage for the average discharge 
rate (spikes per second). Classification of units according to the state in which their 
maximal discharge rate occurred was performed by ANOVA followed by post hoc paired 
t-tests with the Bonferroni correction, (P <0.05) [63]. This analysis allowed the 
classification of units into three main neuronal populations that were shown to respond 
during specific sleep-wake stages (Figure 4B). 
Moreover, to identify the neurons related to feeding behaviour in the LH, we assessed the 
firing rate of neurons that responded after the food was released by aligning the unit firing 
to the pellet release from the CHORA feeder after a spontaneous nose-poke activity. The 
mean baseline firing rate of each neuron was determined in the interval of 5 s before the 
pellet was released. Paired Student’s t-tests were used to classify the firing rate 
differences of the same units before and after the food was released. To motivate the 
mice to perform more trials, they were food deprived for 12-hour during the dark period, 
and the recording session started at the beginning of the light period for the following 2-
hour. Sessions were videotaped and reviewed to eliminate trials in which the mice 




demonstrated that grooming rarely occurred and, thus, did not affect SUA. Indeed, 
grooming has been shown to induce moderate OX neuron activity [146]. Among all 
sessions, a mean of 3.25 ± 1.49 trials for the PWScrm+/p- mice and 2 ± 0.69 trials for the 
PWScrm+/p- mice were removed from the analysis because the food was not eaten. 
 
Statistics 
Values were tested for a Gaussian distribution with the Kolmogorov–Smirnov test. Data 
are presented as the mean ± standard error of the mean (SEM). Two-way repeated-
measures analysis of variance (ANOVA) was used to perform group comparisons with 
multiple measurements. Paired and unpaired t tests were used for single value 
comparisons. One-way ANOVA was used to compare more than two groups, followed by 
post hoc Tukey’s test. The Bonferroni correction was further applied in the post hoc 
analysis, as appropriate, to correct for multiple comparisons. Neuronal dynamics of the 
LH were analyzed by the chi-square test. Phenopy [133] was used for sleep, temperature 
and SUA analyses, while GraphPad Prism6 (GraphPad Prism Software, Inc.) was used for 
statistical analysis. Type I error α was set to 0.05 (p < 0.05).  
For further details of Phenopy system, see appendix A. 
 
3.2 Study II 
In vivo study – Animals  
Animals utilized in this study were the same used in the Study I. For more details regarding 
the animal husbandry, breeding, and genotyping see session 3.1 from Study I. 
 
Experimental design 
For the study, male mice with paternally inherited Snord116 deletions (PWScrm+/p-) and 
wild-type littermate control mice (PWScrm+/p+) aged 15 to 18 weeks were used. 
To investigate the impact of Snord116 in the sleep architecture, we made continuous 
recordings by electroencephalography combined with electromyography (EEG/EMG) for 
24-hour (12-hour:12-hour light/dark cycle). Subsequently, we investigated changes in 
spindle properties at specific time points across the sleep-wake cycle. Specifically, we 
recorded sleep spindles during the same time point of SUA recordings (see experimental 




EEG/EMG electrode implantation 
See Surgery section from Study I. 
 
EEG/EMG analysis 
See Electrophysiological data analysis session of Study I. 
 
REM sleep characterization 
Additional analyses were performed to characterize the REM sleep alterations observed 
in the PWScrm+/p- mice. In particular, a more detailed analysis of REM sleep was carried 
out according to the partition of REM sleep episodes into single and sequential episodes, 
which has originally been proposed for rat [147]. First, the REM sleep intervals (RSIs), 
given by the sum of the time spent in wakefulness and in non-REM sleep between two 
REM sleep episodes, were calculated. Here, the bimodal distribution of RSI length was 
determined using a kernel density estimation mathematical model, and single REM sleep 
episodes and sequential REM sleep episodes were discriminated (Figure S1A). A single RSI 
is defined as one that is both preceded and followed by long RSIs > 60 sec each, while 
sequential REM sleep episodes are those that are separated by short RSIs <= 60 sec each 
(Figure 8A). 
Second, the REM-non-REM cycle, which is defined as the interval between the onset of 
consecutive REM episodes, was assessed. The following criteria were used: 8 sec was the 
minimum length of a REM sleep episode; and cycles that were longer than 30 minutes 
were excluded from the analysis, since it has been already documented in mouse studies 
that the cycle length is approximately 2-5 minutes [148]. An unpaired t-test was used to 
assess differences between short and long RSIs and differences in the number of REM-
non-REM sleep cycles. 
 
Sleep spindle properties 
Individual sleep spindles were detected using a wavelet-based spindle detection method 
[149]. Briefly, the algorithm estimates the energy of EEG signal within 9-16 Hz range using 
the continuous wavelet transform, and then applies a threshold (3 SD + Mean) to detect 
candidate spindles. A lower threshold (1 SD + Mean) is then applied to find start and end 




as spindles; (i) duration between 0.4-2 s, (ii) number of cycles between 5-30 (minimum 
and maximum number of events for the two hour recording), (iii) increase in power should 
be specific to the spindle range. Afterward, several properties of the detected spindles 
are calculated automatically, such as density, duration, central frequency, peak-to-peak 
amplitude, and symmetry. 
 
Neurochemical analysis 
Neurochemical analysis was performed in PWScrm+/p- mice (n = 5) and PWScrm+/p+ mice (n 
= 5). Mice were anaesthetized with isoflurane at the beginning of the dark period to collect 
cerebrospinal fluid (CSF). We decided to collect samples at this time point because REM 
sleep alterations were observed at this stage. CSF was sampled as previously described 
[150]. Mice were anaesthetized using 1.5%–2.5% isoflurane in oxygen and placed on a 
platform, and the arachnoid membrane covering the cisterna magna was punctured. The 
positive flow pressure allows the collection of CSF using a glass micropipette with a 
narrow tip. Three to eight microliters of CSF per mouse was collected and stored at −80 
°C in polypropylene tubes. 
 
CSF preparation for ultrahigh-performance liquid chromatography-tandem mass 
spectrometry (UPLC-MS/MS) 
Eighteen microliters of a solution containing 1 µM each of Glu-d5 and GABA-d6 and 50 
nM His-d4 in aqueous 0.1% formic acid was added to 2 µL of each thawed sample of CSF 
and then vortexed and centrifuged for 10 minutes at 14,000 rpm. The resulting 
supernatants were moved to glass vials for injection. Calibration standards were prepared 
by spiking artificial CSF (150 mM Na, 3 mM K, 1.4 mM Ca, 0.8 mM Mg, 1 mM P, 155 mM 
Cl, 10 mM glucose, 0.5 mg/mL albumin) with stock standard solutions. These calibrators 
were further diluted 1:10 with the internal standard solution, vortexed and centrifuged 
before injection.  
 
UPLC-MS/MS 
Chromatographic separation was performed with an Acquity UPLC system (Waters, 
Milford, MA, USA) using an ACE C18-Ar column (2 µm particle size, 2.1x150 mm 




Separation was carried out at a flow rate of 0.5 mL/min. The eluents were as follows: A, 
aqueous 0.1% formic acid with 5 mM n-perfluoropentanoic acid (NFPA); B, acetonitrile 
with 0.1% formic acid. The gradient used starts with 1 minute at 1% B, increasing linearly 
from 1% to 50% B in 2.5 minutes, and then remaining at 50% B for 30 sec before the 
column was equilibrated with the initial conditions for 2 additional minutes, adding up to 
a run time of 6 minutes. The column and autosampler temperatures were set to 45 and 
10 °C, respectively. The injection volume was set to 4 µL. Analysis was performed on a 
XEVO TQ-S triple quadrupole mass spectrometer (Waters) equipped with an electrospray 
source operated in positive mode. Nitrogen was used as the desolvation (800 L/h, 450 °C) 
and collision gas. Data were acquired in the multiple reaction monitoring (MRM) mode, 
with the settings of the precursors, fragments, cone voltages and collision energies for 
each compound. Waters MassLynx 4.1 and TargetLynx 4.1 software were used for data 
acquisition and processing, respectively. A paired t-test was used to compare the levels of 
each neurotransmitter between the two genotypes. 
This analysis was done in collaboration with Andrea Armirotti from Facility Analytical 
Chemistry and in vivo Pharmacology at Italian Institute of Technology. 
 
Statistical analysis 
The normality of the distribution of values was tested with the Kolmogorov–Smirnov test. 
Data are presented as the mean ± standard error of the mean (SEM). As detailed above 
for the in vivo experiment, most data were analyzed using two-way ANOVA and Student’s 
t-test as appropriate for the experimental design. If the P values reached statistical 
significance, Bonferroni adjustment was further applied for post hoc analysis. For the 
sleep analysis, Phenopy was used [133] while GraphPad Prism6 (GraphPad Prism 
Software, Inc.) was used for statistical analysis. Type I error (α) was set at 0.05 (p < 0.05). 
For MEA recordings, belonging to the in vitro experiment, data were analyzed using two-
way repeated-measures ANOVA (factors=genotype x treatment) followed by Tukey’s post 
hoc test. SigmaPlot software (Systat Software Inc.) was used for statistical analysis to 
compare data from two different populations, we performed the Mann-Whitney test, 






3.3 Study III 
Animals utilized in this study were the same used in the Study I and II. For more details 
regarding the animal husbandry, breeding, and genotyping see session 3.1 from Study I. 
 
Experimental design and drug administration 
For the study, mice with paternally inherited Snord116 deletions (PWScrm+/p-; n=20) and 
wild-type littermate control mice (PWScrm+/p+; n=20) of 12 to 15 weeks of age were 
randomly assigned to two experimental groups:  
i. vehicle-placebo treatment 
ii. Pitolisant treatment. 
 
To investigate the effect of Pitolisant in the sleep-wake cycle, PWScrm+/p+ mice (n=10) and 
PWScrm+/p- mice (n=10) were implanted with electroencephalogram combined with 
electromyogram (EEG/EMG). EEG/EMG were recorded continuously for 24-hour for a 
baseline value (12-hour:12-hour dark-light cycle) and for the following 24-hour after 
either placebo or Pitolisant administration. The placebo (vehicle) consisted of 0.05 ml of 
NaCl at 0.9% containing dimethyl sulfoxide (DMSO; Sigma Aldrich) at 1%. Pitolisant 
(BF2.649, 1-[33]piperidine, hydrochloride) was provided by Pr. Stark H. (University of 
Düsseldorf, Germany) [131] the dosage used was 20 mg/kg as previously described [151]. 
Pitolisant was freshly dissolved in the vehicle, before each administration, and was 
administered orally using a mouse gavage probe (20G, Phymep, Paris) placebo/Pitolisant 
was administrated at the beginning of the dark period (active phase for mice, Figure S1B), 
to preserve the homeostatic and circadian process of sleep. The order of administration 
was randomized. After a period of 7 days (washout-period) Pitolisant/placebo was again 
administered, to perform the neurochemistry analysis (Figure S1C). 
 
Surgery and electrophysiological data analysis 
To investigate the effect of Pitolisant in the sleep wake-cycle we implanted all animals 
with EEG/EMG electrodes. For more details regarding the surgical procedure and the 
electrophysiological data acquisition and analysis see the session 3.1 of the Study I. 
Regarding the statistical analysis in this study, a two-way ANOVA with repeated measures 




time-course changes in the amount of each sleep stages (W, non-REM and REM sleep) 
and physical activity of the baseline together with the day when the two genotypes (+/+ 
vs -/-) received either Pitolisant or placebo. The statistical analysis of the cumulative 
amount of W, non-REM, and REM sleep over the dark and light periods among groups 
who received placebo or Pitolisant was carried out with two-tailed t-test. The cumulative 
amount of physical activity of both genotypes over the dark and light period at the BL and 
after treatment was assessed by one-way ANOVA. A paired t-test was used to compare 
the delta temperature for each genotype before and after treatment.  A two-way ANOVA 
with repeated measures on both factors (group x Hz) was used for the statistical analysis 
of EEG power for REM and non-REM sleep in the corresponding light or dark periods at 
the BL and after administered Pitolisant. 
 
Electrophysiological data analysis 
See Electrophysiological data analysis session of Study I for the analysis of cortical 
EEG/EMG signals. 
A two-way ANOVA with repeated measures on both factors (group x time) was used for 
the statistical analysis of two-hours averaged time-course changes in the amount of each 
sleep stages (W,non-REM and REM sleep) and physical activity of the baseline together 
with the day when the two genotypes (+/+ vs. -/-) received either Pitolisant or placebo. 
The statistical analysis of the cumulative amount of W, non-REM, and REM sleep over the 
dark and light periods among groups who received placebo or Pitolisant was carried out 
with two-tailed t-test. The cumulative amount of physical activity of both genotypes over 
the dark and light period at the BL and after treatment was assessed by one-way ANOVA. 
A paired t-test was used to compare the delta temperature for each genotype before and 
after treatment.  A two-way ANOVA with repeated measures on both factors (group x Hz) 
was used for the statistical analysis of EEG power for REM and non-REM sleep in the 
corresponding light or dark periods at the BL and after administered Pitolisant. 
 
Statistical analysis 
Gaussian distribution of values was tested with the Kolmogorov–Smirnov test. Data was 
presented as mean ± standard error of the mean (SEM). As detailed above, the majority 




experimental design. If the F values reached statistical significance, Turkey adjustment or 
least significant differences (LSDs) were further applied for post-hoc analysis, as 
appropriate for the number of comparisons. For the sleep, temperature and physical 
activity analysis Phenopy was used [133], while GraphPad Prism6 (GraphPad Prism 







4.1 In the Study I, we investigated whether Snord116 may play a role in the 
hypothalamic formation and in the regulation of the biological and homeostatic control 
of sleep. 
 
4.1.1 Loss of paternal Snord116 alters neuronal dynamics in the LH associated with 
sleep homeostasis 
To investigate whether the firing pattern of neurons within the LH manifests signs of 
paternal-dependent subcortical regulation throughout different arousal states of the 
brain, we studied mice with paternal deletion of the Snord116 gene [97], PWScrm+/p- mice, 
and their wild-type littermate controls, PWScrm+/p+ mice. We identified neurons in the LH 
that are time-locked (see Methods and Figure 4A-F for full details on the procedure) to 
sleep (S-max) and to wake (W-max) states and to food intake (Type I, II and III). Strikingly, 
we observed a significant increase in S-max and a reduction in W-max neurons in 
PWScrm+/p- mutant mice compared with controls at baseline (Figure 4G and 
supplementary Table 2). A more detailed analysis of B1 and B2 confirmed this distribution 
of the classes of LH neurons according to EEG states (Figure S2B and supplementary Table 
2. Moreover, when the pressure of sleep is low (i.e., B1), mutant mice exhibit more REM 
sleep than their littermate controls (Figure S2A). This finding suggests that the 
pressure/need of sleep may be either a permissive or a blocking mechanism with respect 
to excess REM sleep due to the lack of Snord116. This phenomenon is confirmed by the 
profile of the power densities in REM sleep (Figure S2C). Indeed, in PWScrm+/p- mutant 
mice, the theta (4.5-9 Hz) band, which is characteristic of REM sleep, is higher in both B1 
and B2, but at B2, the EEG frequency phenotype is not accompanied by longer REM sleep 
duration, implying that the overall higher sleep pressure masks differences in 
microstructural aspects of electrophysiological sleep. Moreover, the delta (0.5-4.5 Hz) 
band presents an opposite trend in the two groups of animals; counterintuitively, reduced 
power is observed in mutant mice as the pressure of sleep increases (Figure S2C). Again, 




Thus, we sought to explore the physiological responses of mice following 6-hour of total 
sleep deprivation (SD) by investigating the distributions of the neuronal classes at 
different time points during 18-hour of recovery (i.e., SD1, SD2 and SD3, Figure 4B). We 
observed that SD induced an increase in S-max neurons in wild-type PWScrm+/p+ mice, 
while in mutant PWScrm+/p- mice, the distribution of classes of neurons remained 
unaltered compared with baseline (Figure 4G). This result indicates that control mice 
homeostatically respond to SD by modulating LH neuronal dynamics, as previously 
reported in the literature [152], while mutant mice lack this hypothalamic modulatory 
process. 
Across different conditions, neurons may continue responding to the same state, may 
respond to different state, or may become aspecific in their activity. Within the 
rearrangements of neuronal modulation across different phases, an interesting 
observation in this study is represented by the behavior of the non-responding neurons 
following SD (Figure S2A, supplementary Table 2). In wild-type mice after SD, the number 
of neurons of this latter class increases three times compared with the previous baseline, 
a phenomenon that is gradually recovered over the following 18-hour after deprivation. 
This change comes with a cost for wake-dependent neurons in wild-type animals. In 
PWScrm+/p- mutants, this SD effect is missing, reinforcing the observation of a lack of 
neuromodulation caused by the paternally derived genetic defect. 
Finally, the dramatic drop in delta and theta power densities in PWScrm+/p- mutant mice 
compared with controls at SD2 (Figure S2C) coincides with the permissive role of sleep 
pressure at this time of the day for the sleep defects in mutants. 
 
4.1.2 OX putative neurons are reduced in PWScrm+/p- mutants compared with controls 
The LH is made by a heterogeneous group of cells that express various neuropeptides, 
such as OX and MCH neurons. To gain insight about the heterogeneous nature of these 
recording units, we plotted the mean firing rate versus the mean logarithm of the EMG 
signals across three groups of putative neurons (W-max; S-max and ws neurons) of the 
whole sleep experiment (Figure S2D). The graphical representation of these neurons 
within the 2D scatter plot enables us to distinguish between MCH putative and OX 
putative neurons. MCH putative neurons fire maximally during REM sleep and are thought 




OX putative neurons fire maximally during wake and are characterized by a high firing 
rate, 3.17 ± 0.79 Hz, as both classes of neurons were previously described [153]. Based on 
these criteria, we assessed MCH putative and OX putative neurons between PWScrm+/p+ 
wild-type and PWScrm+/p- mutant mice. The percentage of recorded MCH putative neurons 
was unchanged between the two genotypes; although non-statistically significant, a total 
of 211 OX putative neurons were identified in PWScrm+/p- mutant mice compared with 315 
OX putative neurons identified in control mice. This observation suggested that PWS 
mutants may express a reduced number of OX neurons in the LH (Figure S2D). 
 
4.1.3 A high proportion of neurons in the LH do not respond to food intake in 
PWScrm+/p- mutant mice 
Mice underwent food deprivation (FD) during the dark period/resting phase (Figure 4B) 
to increase their drive for food intake. When food was made available again, pellets were 
automatically provided in the home cages of each mouse (see Methods). The frequency 
of nose-poke activity to gain food was similar between the two genotypes (PWScrm+/p-: 
107 trials; PWScrm+/p+: 116 trials), indicating no obvious behavioural differences between 
the two genotypes, as previously described [154], [155]. As for the sleep experiment, the 





We found that PWScrm+/p- mutant mice had less than half the number of type II neurons, 
which have reduced firing during food intake, of control mice (Figure 4G). This reduction 
Figure 4, Loss of paternal Snord116 alters neuronal dynamics in the LH associated with sleep and food. 
A) The cartoon on the left shows mice chronically implanted with a microwire array of 16 channels with 
an EEG-EMG wireless transmitter to record the sleep-wake cycle. On the right, a schematic representation 
of the mouse skull depicting EEG, EMG (red circle) and single unit activity (SUA) in the contralateral 
hemisphere is shown. The correct placement of the SUA electrode was histologically verified by 40-μm 
Nissl-stained coronal brain sections (bregma –1.10/–1.90). B) The panel shows a schematic representation 
of the experimental design used to record SUA and the sleep-wake cycle in relation to sleep pressure 
depicted by EEG/EMG. Recordings were performed at two different baseline (BL) time points (B1 and B2) 
over the first hour of the rebound period (SD1) following 6-hour of total sleep deprivation (SD) and at other 
two time points over the 18-hour recovery period (SD2 and SD3). Each recording is 2-h, except for SD1 (1-
hour). Each recording is represented by cyan bars. After 5 days of recovery from the previous SD, the 
animals were fasted for 12-hour during the dark period and fed at the beginning of the light period. Food 
pellets were provided only after a nose-poke activity. SUA was continuously recorded for 2-hour after being 
fed. The black bar indicates the dark period of the light/dark cycle, while the white bar indicates the light 
period of the cycle. C) The panel shows an example of EEG/EMG traces with the sleep stages identified 
(wakefulness is represented in grey, while sleep, including both NREM and REM sleep stages, is shown in 
orange) aligned with the firing rate recorded in the LH. The heatmaps at the bottom show the response 
firing rate in spikes/second from 0 Hz (blue) to 20 Hz (red). D) The heatmaps show the response firing rate 
used to classify neurons before and after food consumption (firing rate in spikes/second from 0 Hz [blue] 
to 20 Hz [red]). E) Violin plots of classified units according to the sleep-wake states in which they maximally 
fired according to ANOVA followed by post hoc Bonferroni correction (p < .05) see Methods. F) Violin plots 
of classified units according to their discharge related to food consumption (paired Student’s t-test of the 
firing rate between before and after the pellet was released, binned at 50 ms, p < 0.05). See Methods. G) 
The pie chart represents the distribution of recorded neurons according sleep-wake stage: wake (W-max), 
sleep (both NREM and REM sleep, S-max) and not responding (ws). The rows show the two genotypes 
(PWScrm+/p+ on the top and PWScrm+/p- on the bottom), while the columns show the different recording time 
points, B, RB and food. According to the neuronal classification (see Methods), W-max neurons are shown 
in green, S-max neurons are shown in blue, and ws neurons are shown in yellow. Type I, neurons that fire 
maximally immediately after nose-poke activity and during feeding shown in grey; Type II, neurons that 
show a sharp increase in firing rate at the beginning of feeding shown in green; Type III, neurons that do 
not respond to food shown in red. Differences between the two genotypes are indicated by $, while 
differences within groups across time points are indicated by §. Significance was computed with the chi-
square test; for details on the statistical analysis, see Table S2, S3 and S4. The two genotypes investigated 





may be explained by the fact that mutant mice had twice as many non-responding 
neurons as control mice. Indeed, type I neurons were almost identical in the two groups 
(supplementary Table 2). These results also suggest for an abnormal distribution of OX 
neurons in the LH of mutants, as OX neurons drive food intake. 
 
4.1.4 Sleep homeostasis is disrupted in PWS mutant mice 
We explored the 24-hour EEG profile of sleep (see Methods) and the responses to sleep 
loss in a different cohort of animals. 
The results confirmed our previous observations that sleep is altered in the PWS mutants 
[100]. In particular, REM sleep is increased in PWScrm+/p- mutants compared with controls, 
showing a peak increase at ZT (Zeitgeber Time) 20 and an overall increase in theta power 
(Figure 5A). These experiments were conducted at standard room temperature of 22°C. 
Interestingly, the theta profile in mutants did not show circadian rhythm (Figure 5A); 
PWScrm+/p- mutants had an increase in theta power during the transition between light 
and dark, when the pressure of sleep is low. Overall, REM sleep abnormalities remained 
a selective phenotype in these mutants, while the other EEG-determined arousal states 
were unchanged between the two genotypes (Figure S3A). 
Moreover, we tested for the first time the homeostatic EEG response following SD in 
PWScrm+/p- mutant mice compared with littermate controls. Compared with control mice, 
PWScrm+/p- mice showed reduced delta activity during non-REM sleep rebound following 
SD (Figure 5B), although the total amount of non-REM sleep was unaltered over the long-
term recovery process (Figure S3A). Notably, delta power is the best electrophysiological 
marker of sleep propensity, although the temporal distribution of its rebound following 
SD is less characterized. The behavior of delta sleep in mutant mice suggests a 
dysregulation in the daily distribution of sleep pressure in these mice. 
These results also showed a significant decrease in REM sleep during the first 2-hour of 
rebound in mutants compared with controls (Figure 5A), confirming both the alteration 
of homeostatic control in mutants and the alteration of REM sleep. 
 
4.1.5 Thermoneutrality does not increase REM sleep in mutants 
REM sleep is an evolutionarily recent physiological state of sleep that, in mammals, is 




sleep expression in mice is attained when the environmental temperature is near 29°C. 
The latter represents a thermoneutral zone (TNZ) for this species [158]. 
In a new set of experiments, we modified the temperature environment of the animals to 
allow the duration of REM sleep to reach a maximum [158]. Mice were housed for 5 weeks 
at 30°C, and then, EEG/EMG were recorded for 24-hour at the TNZ. Mutant mice showed 
a significant increase in all sleep stages (Figure S3A-B) compared with wild-type mice, but 
REM sleep did not significantly increase in the mutant mice, perhaps due to the high REM 
sleep percentage at baseline (Figures 5A, S3C and S3D). However, PWScrm+/p- mutant mice 
maintained a significant increase in REM sleep compared with controls at ZT 20 (Figures 
5A and S3A). 
 
4.1.6 Peripheral thermoregulatory responses are absent in PWS mutants 
We tested whether loss of paternally expressed Snord116 affects peripheral responses 
and whether these changes impact the overall body temperature and body weight of the 
animals. We monitored the peripheral and cutaneous body temperature at the head (T-
head) and tail (T-tail), and consequently, we derived the heat loss index (HLI) (see 
Methods). Recordings were made at room temperatures of both 22°C and 29-30°C (TNZ). 
The TNZ imposes body temperature adjustments by changing the vasomotor tone in 
specialized heat exchange organs, such as the tail, in mice [159]. We observed an increase 
in the vasculature tail skin tone at the TNZ in both genotypes compared with 22°C (Figure 
5C, upper panel). However, greater tail vasodilatation was observed in control mice, 
particularly between the switch from light to dark periods. These results indicate that 
while at TNZ, wild-type control mice present a proper peripheral thermoregulatory 
response when the pressure of sleep is low, which is instrumental in maintaining the core 
body temperature of the animal at this time of the day, mutant mice lack such an 
important physiological response. A significant increase in the HLI was recorded in both 
genotypes, but a greater increase was found in PWScrm+/p+ wild-type mice than in mutant 
mice (Figure 5C, middle panel). We also observed that the peripheral body temperature 
recorded at 22°C increased in PWScrm+/p- mutant mice compared with control mice during 
the light period (Figure 5C, bottom panel), suggesting a lack of homeostatic control when 
sleep is physiologically facilitated in mice. Moreover, mutant mice failed to show the 




However, at TNZ, the difference between the two genotypes during the light period was 
no longer observed. Furthermore, in agreement with previous reports [155], we observed 
that PWScrm+/p- mutant mice had a smaller body size when kept at 22°C (Figure S4). 
Interestingly, the smaller body size was observed both when the mutant mice were 
exposed to 30°C later in their development (e.g., for only 5 weeks) and when they were 
exposed to the TNZ from birth and kept at the TNZ for up to 20 weeks of age (Figure S4). 
However, while the former 5-week experimental strategy resulted in an increase in body 
weight in both cohorts of animals, which was more pronounced in wild-type animals than 
in mutants, the latter (birth) strategy resulted in no changes over time according to 
temperature (Figure S4). Notably, maintaining at the TNZ from birth resulted in an overall 
body weight in mutants that was comparable to the body weight at RT. The latter 
observation suggests that the TNZ is a condition that permits an increase in body weight 
in PWS animals, although this cannot neutralize the differences with wild type animals 
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Figure 5, Snord116 influenced REM sleep and its homeostatic regulation, thermoregulatory response via 
the orexin system. A) Left panel, REM sleep distribution over an uninterrupted 24-hour period over a 12-h 
light/dark cycle as baseline values and the following 18-hour after total SD. Recordings were made with 




REM sleep was significantly altered in mutant mice relative to control mice at baseline and over the 
recovery period following 6-h of SD (two-way ANOVA: F (20, 160) = 8.66 p= <0.0001; “time”; F (8, 160) = 
3.33; p= <0.001; “genotypes”). REM sleep was also altered in mutant mice relative to control mice when 
the sleep-wake cycle was recorded at the TNZ (two-way ANOVA: F (11, 88) = 11.61 p= <0.0001; “time”). 
Data are reported as the percentage in 2-hour bins, averaged within genotypes (mean ± SEM; n = 5 
PWScrm+/p+ and n = 5 PWScrm+/p- mice). PWScrm+/p- mice are represented by red circles, while control mice 
are represented by black circles. 
Middle panel, the cumulative amount (mean ± SEM) of REM sleep during the 12-hour of the light period 
(white bar above the bars) and during the 12-hour of the dark period (black bar above the bars) for the 
three groups investigated (recordings at 22°C are shown in blue, after 6-h of SD in white and at 30°C in 
orange). The within-group statistical analysis was performed by one-way ANOVA, followed by a post hoc 
analysis with the Bonferroni multiple comparison test. During the dark period, PWScrm+/p- mice showed an 
increase in REM sleep (F(1.85, 4.74)= 18.06, p = .0082). Student’s unpaired t-test between genotypes 
indicates an increase in REM sleep in PWScrm+/p- mutant mice relative to PWScrm+/p+ mice (t(8) = 2.30, p = 
.04). The right panel shows the spectral analysis. Theta power at 22°C between genotypes. The theta power 
of each subject was normalized by the mean of the last 4-hour of the light period. Theta power during REM 
sleep was increased in PWScrm+/p− mice (two-way ANOVA:, F(11,88)= 3.08, p = <.001 “time”; F(1,8)= 8.04, 
p= .02 “genotypes”). Data are reported in 2-hour bins and are shown as the mean ± SEM. B) The panel 
shows the delta power at 22°C between baseline vs rebound for PWScrm+/p+ and PWScrm+/p- mice. The delta 
power of each subject was normalized by the mean of the last 4-hour of the light period. Wild-type mice 
displayed a significant increase in delta power following SD from ZT 6 to ZT 10 (two-way ANOVA: F(11,88)= 
28,77 p= <0.0001 “interaction”), while mutant mice showed a mild increase only at ZT 6 (two-way ANOVA: 
F(11,88)= 12,25 p= <0.0001 “interaction”). Data are reported in 2-hour bins and are shown as the mean ± 
SEM. Right panel, the average of the first 4-h of recovery after SD between the two genotypes for the delta 
power. PWScrm+/p- mice showed lower delta than PWScrm+/p+ mice (unpaired t-test: t(8) = 2.31, p = .04). 
Values are reported as the mean ± SEM. Asterisks (*) indicate a significant difference between genotypes: 
* P ≤ .05; **p ≤ .01; *** p ≤ .001; **** p ≤ .0001. Two genotypes were investigated: PWScrm+/p− mice (n= 
10, 5 mice at 22°C and 5 mice at 30°C) and PWScrm+/p+ mice (n= 10, 5 mice at 22°C and 5 mice at 30°C). C) 
Temperature profile for PWScrm+/p+ and PWScrm+/p-. The top panel shows the T-tail profile recorded with an 
infrared thermocamera over 24-hour. Recordings were performed under two different environmental 
conditions: at 22°C (cyan bar over the graph, shown on the left) and at 30°C, corresponding to the 
thermoneutrality zone (TNZ) (orange bar over the graph, shown on the right). Middle panel, the heat loss 
index (HLI) was calculated according to the following formula: ("#$%&'()#("&)("#*&'+)#("&)  (see Methods) and assessed 
at 22°C (left) and at the TNZ (right). Bottom panel, the core body temperature profile recorded 
simultaneously with EEG over 24-hour was recorded using a telemetric system in which the probe was 
subcutaneously implanted. PWScrm+/p- mice are represented by red circles, while PWScrm+/p+ mice are 
represented by black circles. Values are expressed as a 2-hour mean ± SEM. At 22°C, no differences were 







4.1.7 Lack of Snord116 impairs the OX system in the LH 
To assess the regulation of the main neuropeptides in the LH, we examined the expression 
of OX and MCH. Thus, we assessed the precursor of MCH (Pmch) and the prepro-OX 
(Ppox). I examined three conditions (Figure S5A): at ZT 6, we tested both the baseline 
condition (T0) and the effects of SD (T1); and at ZT 7, 1-hour after SD (T2), we tested the 
effects during the recovery from the loss of sleep. 
We observed that PWScrm+/p- mutant mice showed a significant increase in Ppox at T0 
baseline compared with control mice, while Pmch was unchanged in both genotypes at 
T0 (Figure 5D). At T1, both Ppox and Pmch were significantly reduced in PWScrm+/p- mice 
compared with control mice (Figure S5B), confirming that the homeostatic response in 
mutants is reduced and that these two systems are dysregulated in mutant mice. At T2, 
the difference between the two genotypes for Ppox and Pmch was repristinated (Figure 
S5B), confirming that the effects of SD in mutants are only acute and follow the immediate 
response after sleep deprivation. 
PWScrm+/p- mice showed an increase in body temperature during the light period at ZT 6 at 22°C (two-way 
ANOVA: F(11,88)= 3.53, p = .0004 “time”; F(11,88)= 7.86, p = <.0001 “genotypes”). At 30°C, T-tail (two-
way ANOVA: F(11,88)= 2.68, p = <.0001; “interaction”) and HLI (two-way ANOVA: main effect of time-of-
day, F(11,88)= 4.72, p = <.0001 “interaction”) were increased in PWScrm+/p+ mice relative to mutant mice. 
No differences in body temperature were observed at 30°C. Asterisks (*) indicate a significant difference 
between genotypes (* P ≤ .05). Two genotypes were investigated: PWScrm+/p− mice (n= 10, 5 mice at 22°C 
and 5 mice at 30°C) and PWScrm+/p+ mice (n= 10, 5 mice at 22°C and 5 mice at 30°C). D) Ppox and Pmch 
gene expression analysis in PWScrm+/p− mice versus controls. PWScrm+/p− mice (red bar) showed an increase 
in Ppox (unpaired t-test: t(8) = 2.49, p = .03) compared with PWScrm+/p+ mice (black bar).  
No differences in the mRNA Pmch level was observed between the two genotypes. Values are reported as 
the mean ± SEM. Asterisks (*) indicate a significant difference between genotypes: * P ≤ .05. E) Cell count 
distribution of orexin (OX) immunoreactive neurons (upper) and melanin concentrate hormone (MCH) 
immunoreactive neurons (below) in the lateral hypothalamus of PWScrm+/p− mice (right) versus controls 
(left). Coronal sections were stained with OX- and MCH-specific antibodies, counterstained with DAPI and 
scored. Values are expressed as the percentage of positive neurons relative to all stained nuclei (mean ± 
SEM). The number of OX+ neurons was reduced in the PWScrm+/p− mouse group (unpaired t-test: t(33) = 
3.85, p = .0005). No differences were found in the number of MCH+ neurons. Asterisks (*) indicate a 
significant difference between genotypes: *** p ≤ .001. Two genotypes were investigated: PWScrm+/p− mice 





Then, we evaluated the receptors. We assessed mRNA levels of OX receptor-1 (Ox1R) OX 
receptor-2 (Ox2R) and MCH receptor 1 (Mch1R) in the hypothalamus and in other brain 
areas as control measures. The expression levels were overall unchanged between the 
two genotypes, except for Ox2R in the parietal cortex (Figure S5C). 
The overall contrast between neuropeptides and the mRNA levels of their receptors 
prompted us to quantify whether these chemical changes within the OX and MCH systems 
had consequences for the organization of the neuronal populations of the LH. We 
observed a significant reduction in OX neurons in the LH of PWScrm+/p- mutant mice 
(PWScrm+/p+ mice 95  ± 9; PWScrm+/p- mice 53  ± 10; p= .0005; Figure 5E), while MCH 
neurons, which are located near the OX neurons, were unaffected (PWScrm+/p+ mice 66 
 ± 5; PWScrm+/p- mice 63  ± 5; Figure 5E). The discrepancy between the increased Ppox and 
the reduced neuronal population may be due to a mechanism to compensate for the low 
number of neurons with an overproduction of the peptide. 
 
4.1.8 Loss of Snord116 leads to transcriptional reprogramming in the hypothalamus 
Next, we investigated whether the loss of Snord116 affects overall gene expression in the 
hypothalamus of PWScrm+/p− mutant mice compared with PWScrm+/p+ control mice by 
performing RNA sequencing (RNA-seq). The mice were investigated at the beginning of 
the light period ZT 0 (group 1, G1), 6-hour later at ZT 6 (group 2, G2) and at ZT 6 but 
following 6-hour of SD (group 3, G3). First, we sought to identify the differentially 
expressed genes (DEGs) between the two genotypes in the G1 group. We identified 4777 
downregulated genes and 4271 upregulated genes between genotypes (adjusted p < 0.05; 
see Methods) and a minimum fold change of 2 (supplementary Table 4). Next, we 
compared the down- and upregulated DEGs (Figure 6A-B) in G1 PWScrm+/p− mutant mice 
with DEGs derived from post-mortem hypothalamic data from PWS patients vs normal 
patients [160]. More than 40% of human DEGs overlapped with mouse DEGs, suggesting 
that loss of Snord116 recapitulates approximately 40% of the transcriptional changes 
found in the human hypothalamus. To more closely evaluate the functional importance 
of these overlapping DEGs, we performed gene ontology (GO) enrichment analysis using 
Metascape [161]. We found enrichment of several biological processes important for 




systems were the processes significantly enriched among the upregulated DEGs (Figure 
6A-B). 
Interestingly, we found that Ppox was significantly downregulated in PWScrm+/p− mutant 
mice and in human PWS patients (Figure 6C), confirming that OX is involved in the 
abnormal regulation of REM sleep in PWS. 
Then, we focused on how SD affects gene expression in the hypothalamus in both normal 
and PWScrm+/p− mutant mice. We compared DEGs in G2 versus G3 of each genotype 
(Figure 6D). We found that 6-hour of SD largely influenced the transcriptome of mutant 
mice (i.e., 833 DEGs) compared with control mice (i.e., 30 DEGs). Surprisingly, in the 
mutant dataset, most of the DEGs were downregulated (804 genes downregulated vs 29 
upregulated). GO analysis of all 833 DEGs revealed enrichment of cell organization, 
development and growth-related processes (Figure 6E), indicating that poor sleep 
negatively impacts the hypothalamus in PWS subjects. Finally, we investigated the RNA-
seq dataset to determine whether Snord116 loss significantly affects the expression of 
imprinted genes in humans and mice (refer to supplementary Table 4). Maternally 
expressed imprinted genes, such as Meg3, Gnas, and H19, as well as paternally expressed 
imprinted genes, such as Nap1l5 and Peg3, were differentially expressed in mutant mice 














4.1.9 OX regulation in the hypothalamus depends on two paternally expressed genes, 
Snord116 and Peg3 
We next sought to confirm selected physiologically relevant DEGs identified within the 
RNA sequencing dataset by qRT-PCR. Among maternally and paternally imprinted genes 
that were altered in the hypothalamus of PWScrm+/p- mutant mice, Peg3 was the only 
confirmed gene, showing a remarkable increase in expression in PWScrm+/p- mice (Figure 
7A) compared with the control mice (Figure S6A). Peg3 binds to DNA based on its multiple 
zinc finger motifs and nuclear localization [162], [163]. Interestingly, a recent study found 
an association between Peg3 and OX expression [164]. However, whether Peg3 is able to 
bind and regulate the expression of OX in living mice remains unclear. We noticed that 
two conserved promoter regions within a 3.2-kb fragment located upstream of the Ppox 
gene (Figure S6F) target specific expression within the LH [165]. We showed that PEG3 
binds one of these regions. Specifically, chromatin immunoprecipitation analysis (ChIP) 
[166] followed by quantitative real-time PCR (ChIP qRT-PCR, and Figure 7A) revealed that 
PEG3 binds the 2.5 kb OX regulatory element region in the hypothalamic mouse brain. 
Interestingly, a significant reduction in PEG3 binding was observed in PWScrm+/p- mice 
(Figure 7A), which may be associated with a significant reduction in OX-expressing 
neurons in mutant mice. These results show that PEG3 positively regulates the expression 
of Ppox by enhancing its expression, as indicated by the presence of a strong enrichment 
of the H3K4me2/3 in the same region (Figure 7A). Conversely, H3K27me3, which is a 
Figure 6, Snord116 loss significantly impacts molecular machinery in the hypothalamus. A-B) Venn 
diagrams illustrating the number of differentially expressed genes (DEGs) that are down- (A) and 
upregulated (B) in the hypothalamus of Prader–Willi syndrome (PWS) PWScrm+/p− mice relative to control 
mice and that overlap in human patients (according to [160]). The results of gene ontology (GO) 
enrichment analysis of biological processes for the overlapping DEGs are also shown in both A and B. C) 
Volcano plots of 637 and 727 DEGs in PWScrm+/p− mice in group 1 (G1; non-sleep deprived). D) Significantly 
down- and upregulated genes in the hypothalamus of PWScrm+/p− mutant mice compared with PWScrm+/p+ 
control mice affected by sleep deprivation (G2 vs G3). E) GO enrichment analysis of biological processes 
for 833 (804 down- and 29 upregulated genes in panel D) DEGs in PWScrm+/p−mutant mice that are 
significantly affected by sleep deprivation. F) Heatmap of the relative expression of imprinted genes 
common in humans and mice assessed in PWScrm+/p− mutant mice compared with the PWScrm+/p+ mice in 





marker of condensed chromatin [167], showed no enrichment in either genotype. The 
GAPDH promoter was used as a negative control for the ChIP experiment (Figure S6E). 
These data reinforce the evidence that PEG3 contributes to the regulation of Ppox by 
enhancing its expression (Figure 7A). 
Then, we sought to investigate whether Peg3 or Snord116 plays any causal role in the 
regulation and formation of OX neurons, and we assessed the expression of these two 
genes in OX-deficient mice. Specifically, we used two genetic mouse models of OX 
deficiency, Ppox knockout (KO) mice [130] and OX neuron-ablated (ataxin-3 [Atx]) mice 
[168] (Figure 7B). 
Atx mice selectively degenerate postnatally, and a loss of 99% of neurons or more occurs 
by the age of 4 months [168]. Therefore, in Atx mice, not only are OX neurons ablated, 
but co-transmitters are also eliminated [169]. Conversely, KO mice are only deficient in 
Ppox (Figure 7B). 
Interestingly, we observed that Peg3 was significantly increased in Atx mice compared 
with KO mice (p= .03). Moreover, Snord116 was also increased in Atx mice compared with 
KO mice and control mice (p= .03; Figure 7B). Other imprinted genes tested were 
unchanged between genotypes (Figure S6B). These data suggest that dysregulation of 
both Snord116 and Peg3 are important and associated with the physiological 
maintenance of OX neurons. Indeed, we observed that both genes were significantly 
altered only in narcoleptic mice, in which OX neurons and their co-transmitters were 
ablated, but not in narcoleptic mice lacking only Ppox. 
Finally, to test whether the alteration of Peg3 observed in the PWScrm+/p- mice and in the 
Atx mice is linked to the absence of Snord116 and whether Snord116 modulates the 
expression of Peg3, we used an RNA-interfering approach aimed at silencing Snord116 in 
immortalized embryonic rat hypothalamus cells (embryonic rat hypothalamus cell line 
R7).  
Specifically, cells transfected with a Snord116-specific siRNA showed significant Snord116 
inhibition of approximately 80% at 48-hour after transfection (Figure 7C). However, the 
levels of Peg3 were unchanged (Figure 7C), indicating that Snord116 does not regulate the 








































































































































Figure 7, Snord116 and Peg3 play roles in the formation and maintenance of OX neurons. 
Peg3 regulates orexin expression in an independent manner from paternal Snord116. A) Upper panel, the 
gene expression analysis of Peg3 in PWScrm+/p− mice (red) versus controls (black). Peg3 mRNA assessed by 
qRT-PCR was significantly increased in PWScrm+/p− mice compared with PWScrm+/p+ mice (unpaired t-test: 
t(6) = 2.45, p = .04). Values expressed are relative to the wild-type control mean ± SEM. Gapdh was used 
as a housekeeping gene; see Methods. Asterisks (*) indicate a significant difference between genotypes. 
Bottom panel, ChIP analysis of PEG3 binding to the Ppox promoter region in PWScrm+/p− mice (red) versus 
controls (black). PEG3 binding was lower in PWScrm+/p- mice than in PWScrm+/p+ mice (unpaired t-test: t(2) 
= 7.11, p = .01). Values are expressed as the mean of the input ± standard deviation. Asterisks (*) indicate 
a significant difference between genotypes. Figure 7  
B) Peg3 gene expression (upper panel) and Snord116 gene expression (bottom panel) in Ppox knockout 
(KO) and orexin neuron-ablated (ataxin-3 [Atx] mice). One-way ANOVA indicated that Peg3 was 
significantly increased in Atx mice relative to KO mice, (F(2,16)= 0.02, Bonferroni post hoc test p = .03). 
Snord116 was increased in Atx mice relative to KO and control mice (WT) (one-way ANOVA F(2,16)= 3.50, 
Bonferroni post hoc test p = .002). Values are reported as the mean ± SEM. Asterisks (*) indicate a 






4.2 In the Study II, we investigated the role of Snord116 in the regulation of the 
macrostructural sleep aspects and in the bran-circuits involved such as the thalamic 
reticular nucleus (TRN)/ thalamus circuits or in corticothalamic afferents. 
 
4.2.1  Paternal Snord116 deletion impacts the macrostructural sleep aspects in mice 
Since the EEG analysis in the Study I highlighted an alteration of REM sleep, which reflects 
a change in the distribution of REM periods with no effects on total sleep or wakefulness, 
we further explored the duration of REM sleep episodes in detail. These results show, for 
the first time, the presence of a bimodal distribution of RSI in mice. RSI was bimodally 
distributed in both genotypes of mice over the 24-hour circadian period, with the two 
clusters separated at 55 sec, which accounts for the minimum frequency (Figure 8A). 
Based on these parameters, the two subpopulations of RSI detected were used to 
distinguish single REM sleep episodes (long RSI >60 sec) and sequential REM sleep 
episodes (short RSI ≤60 sec). Although a bimodal distribution was observed in both 
genotypes of mice, the frequency of short RSIs was significantly higher in the PWScrm+/p- 
mice than in the PWScrm+/p+ mice (PWScrm+/p+ 3.40 ± 0.99 vs PWScrm+/p+ 7.6 ± 1.6, t(18)= 
2.21, p=0.03; Figure 8A), suggesting a high REM sleep propensity in the mutant mice. 
Conversely, the numbers of long RSIs were unchanged between the two genotypes (Figure 
8A). In addition, the REM-non-REM cycle was analyzed as an identifier of sleep propensity 
[170]. These data showed that the cycle length was approximately 2-5 minutes in both 
genotypes of mice, as already described [148]. However, in the PWScrm+/p- mice, a large 
increase in REM-non-REM cycles was observed over the 24-hour of the sleep-wake cycle 
(PWScrm+/p+ 9.00 ± 2.06 vs PWScrm+/p+ 15.15 ± 1.51, t(18)= 2.40, p=0.02; Figure 8A). 
 
The following genotypes of narcoleptic mice were investigated: WT (n=4), KO (n= 12) and Atx (n=4). C) 
Snord116 and Peg3 gene expression analysis in the Snord116-siRNA-treated immortalised hypothalamic 
rat cell line. Snord116-siRNA (green bars) reduced the expression of the Snord116 gene compared with 
untreated cells or scrambled siRNA-treated cells (white and orange bars) (one-way ANOVA: F(2, 6)= 11.36, 
Bonferroni post hoc test p = .009). Peg3 mRNA levels were unchanged, similar to Snord116-SiRNA, in 
untreated cells and scrambled siRNA-treated cells. The experiment was conducted in triplicate. Data are 
presented as the mean ± SEM. Asterisks (*) indicate a significant difference between genotypes: * P ≤ .05; 





4.2.2 Paternal deletion of Snord116 alters sleep spindles in PWS mice 
Sleep spindle properties were explored in relation to the circadian and homeostatic 
components of sleep (Figure 8D). Sleep spindles are the best-characterized source of EEG 
power in the 9–16 Hz range during non-REM sleep (see Figure 8B). We calculated these 
spindle properties for each genotype at different time points and found that the density 
of spindles was unchanged between the two genotypes in all conditions investigated 
(Figure 8C). However, we observed that spindle duration (t(1988)= 3.04, p=0.002; Figure 
8D), central frequency (t(1988)= 2.70, p=0.006; Figure 8D), and the number of spindle 
cycles (t(1988)= 3.47, p=0.005; Figure 8D) were significantly increased in the PWScrm+/p- 
mutants compared to the control mice. Conversely, spindle amplitude was significantly 
lower in the PWScrm+/p- mutants compared to the PWScrm+/p- mice (t(1988)= 18.59, 
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Figure 8, Paternal Snord116 deletion impacts REM sleep and NREM sleep spindles:   
A) On the top, schematic representation of the criteria for the recognition of short-RSI and long-RSI. On 
the middle average frequency distribution of the duration of the interval from the end of one REM sleep 
episode to the beginning of the next REM sleep episode (REM sleep interval, RSI) recorded over the 24-
hour of the sleep-wake cycles in PWScrm+/p+ (n= 10 in black) and PWScrm+/p- mice (n= 10 in red). The 
frequency class which was taken as the boundary separating short and long-interval populations 
(minimum) is at 55-sec. Right, average value of the occurrence of the short and long-RSI for each genotype, 





4.2.3 PWS mutants show increased spontaneous physical activity over the circadian 
cycle 
Physical activity was assessed in awake mice without any motor constraints. During the 
24-hour of the circadian period, both genotypes showed an increase in physical activity 
during the night and a decrease in motility during the day. Interestingly, mutant mice 
displayed an increase in spontaneous physical activity during the subjective night (light 
phase, resting phase for mice) compared to control mice (PWScrm+/p+ 2.48 ± 0.44 vs 
PWScrm+/p+ 3.96 ± 0.33, t(18)= 2.6, p=0.01; Figure 9A). Moreover, physical activity was also 
increased in the mutant mice during the first hours of the dark period compared to the 
motor activity of control mice (two-way ANOVA: F(11,99) = 9.318, p<0.0001, “time of 



































































On the bottom, histograms of sleep cycle length during the 24-hour of the sleep-wake cycle in PWScrm+/p+ 
(n= 10 in black) and PWScrm+/p- mice (n= 10 in red). Sleep cycles are plotted for 3-hour bins. Only data up 
to 30 min are shown. Four combinations of criteria (see Method section). Cycles containing wake 
sequences >64 s were discarded from the analysis. On the right the average value of the number of the 
cycle length around 2-5 minutes in both genotypes of mice. B) Schematic representation of the spindles 
signal; C) The number of the spindles estimated over the 24-hour of the sleep-wake cycles in both 
genotypes, PWScrm+/p+ (n= 10 in black) and PWScrm+/p- mice (n= 10 in red). D) Sleep spindles properties: 
duration between 0.4-2 s, central frequency, peak-to-peak amplitude, number of cycles between 5-30 and 
symmetry. Values are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 
Figure 9, Paternal Snord116 deletion increases physical activity and norepinephrine levels. 
 A) On the left, telemetry measurements of daily activity in home cages monitored 24-hour per day in 
PWScrm+/p+ (n= 10 in black) and PWScrm+/p- mice (n= 10 in red). On the right the spontaneous physical 






4.2.4 Paternal Snord116 deletion leads to dysregulation of norepinephrine 
Neuromodulators are fundamental players in the regulation of sleep-wake cycles. Here, 
we reported an assessment of the levels of glycine, glutamate, norepinephrine, histamine 
and GABA in the CSF of both genotypes. Notably, among all the investigated 
neuropeptides, it was found that the levels of norepinephrine, a neurotransmitter that is 
involved in arousal and is also important for the regulation of REM sleep [41], [171], was 
significantly increased in the PWScrm+/p- mice relative to the control (PWScrm+/p+ 0.53 ± 
0.07 vs PWScrm+/p+ 0.08 ± 0.01, t(8)= 6.22, p=0.0003; Figure 9B). 
  
B) Levels of neurotransmitters (Glycine, glutamate, norepinephrine, histamine and GABA) assessed in the 
CSF of PWScrm+/p+ (n= 10 in black) and PWScrm+/p- mice (n= 10 in red). Mice were sacrificed at the beginning 





4.3 In the Study III, we investigated a new alternative pharmacological approach for 
PWS aimed at ameliorating the sleep disturbances that significantly comprise the quality 
of life of these patients by using Pitolisant in mice carrying the deletion of the Snord116 
gene. 
 
4.3.1 Effect of Pitolisant on the Sleep-wake cycle 
To assess the effect of Pitolisant on the sleep-wake cycle EEG/EMG was recorded over a 
24-hour period (12-hour:12-hour dark-light cycle) as a baseline condition (BL) where mice 
were left undisturbed, and for the following 24-hour after placebo/Pitolisant 
administration. There was no mortality in animals randomized into the placebo (n = 10) 
and Pitolisant (n= 10) groups. To maintain, the within-subjects nature of the protocol the 
24-hour of baseline values were always plotted with its corresponding 24-hour treatments 
(placebo/Pitolsant) for each mouse (Figure 10A). To demonstrate that the effect of 
Pitolisant is not given by chance, manipulation or confounding factors the changes in the 
sleep patterns over the 12-hour dark and 12-hour light were plotted in comparison to 
placebo groups (Figure 10B).  
At the BL both genotypes exhibited circadian changes in sleep-wake cycle, showing a high 
amount of wakefulness during the night and low amount during the 12-hour of the day 
(Figure 10A), typical of nocturnal rodents.  The distribution of all sleep stages (total sleep, 
REM and non-REM sleep) in both genotypes mice similarly varied across the 24-hour of 
BL with less time spent in sleep during the dark period (Figure 10A). However, only the 
percentage of REM sleep during the dark period (p= .045, Figure 10B), were significantly 
increased in the PWScrm+/p- mutants compared to their littermate controls as previously 
shown [100], while the percentage of total sleep and non-REM sleep was unchanged 
between the two genotypes of mice over the dark and light periods (Figure 10B). 
Overall, mutant mice only present at the BL an alteration of REM sleep during the active 
phase of mice (dark period), which reflects a change in the microstructure of sleep without 
affecting the daily amount of wakefulness, total sleep, non-REM sleep. 
Pitolisant, which is a wake-promoting drug, was administrated orally at the beginning of 
the dark period. The placebo was administered at the same time as the Pitolisant in 
PWScrm+/p+ mice and PWScrm+/p- mice and no effect was observed for all sleep parameters 




Pitolisant, as expected, enhanced wakefulness in the PWScrm+/p+ mice during the night 
compared to the placebo group (p= < .0001, Figure 10B). Conversely, in the PWScrm+/p- 
mice only a slight and not significant increase of wakefulness was observed relative to 
placebo. Consequently, this increase in wakefulness during the night reflects a significant 
reduction in the total amount of sleep, only for the PWScrm+/p+ mice relative to the placebo 
group (p= < .0001, Figure 10B), while as observed for the wake state, also the total amount 
of sleep during the night was unchanged in the mutant mice compared to placebo.  
However, although Pitolisant did not significantly affect wake and total sleep in the 
mutant mice, but significantly impact the microstructure of sleep, particularly the REM 
sleep. Indeed, REM sleep was the only stage of sleep that was significantly reduced in both 
genotypes of mice during the night relative to placebo groups (PWScrm+/p+: p= .020; 
PWScrm+/p-: p= .019, Figure 10B).  
The response of non-REM sleep to Pitolisant treatment displayed by both genotypes of 
mice was reminiscent of the same response observed for their respective patterns; 
wakefulness, and total sleep. Specifically, PWScrm+/p+ mice exhibited a significant 
reduction of non-REM sleep during the night (p=< .0001, Figure 10B) compared to the 
placebo group, given by Pitolisant treatment. No significant effect of Pitolisant was 
observed on non-REM sleep in the PWScrm+/p- mice during the night relative to the placebo 
group.  
During the day the total amount of wake, total sleep, and non-REM sleep were unaffected 
by Pitolisant in both genotypes of mice (Figure 10B). However, when I looked at their 
distribution significant differences were observed only in the control mice over the first 
4-hour of light period. Specifically, decreases of wakefulness, which reflects a reduction 
in the total sleep and non-REM sleep were observed (p= < .0001, Figure 10A). This increase 
of sleep over the first 4-hour of the day observed in the control mice, as a sort of rebound 
given by e significant reduction of sleep during the night was not observed in the mutant 
mice (Figure 10A). Although, Pitolsant did not impact the sleep architecture 12-hour after 
its administration suggesting that its effect vanish during the day, however, the only stage 
of sleep that remained altered compared to placebo group even through the light period 
is the REM sleep, and this reduction was observed only in the control mice (p= .040 vs 
placebo group, Figure 10B), Conversely, the mutant mice recovered faster reaching the 




Moreover, dynamics of EEG activity during REM and non-REM sleep were computed over 
the 12-hour of dark and light periods at the BL and after Pitolisant administration.  
At the BL REM sleep power densities in the theta activity (6 – 9 Hz) were unchanged 
between the two genotypes of mice over the dark and light period, although during light 
period, a decrease in the power of theta activity was observed in both mouse lines. After 
administrating Pitolisant the power of theta activity in the control mice was flatted in the 
frequency ranges of 1-10 Hz (Figure 10C and Figure S7A), which reflects a marked 
reduction of REM sleep observed in these mice during the dark period. Conversely, the 
REM sleep power densities in mutant mice showed the same distribution as observed in 
the BL (Figure 10C) and was unaltered compared to placebo except in the frequency 
ranges of 3-3.5 Hz (Figure S7A), although REM sleep was significantly reduced at this stage. 
During the light period, no differences were observed for the power during REM sleep 
between the two genotypes of mice suggesting as even observed for the sleep 
architecture that the effect of Pitolisant vanishes during the day and its action is limited 
to the 12-hour of the dark period. 
As observed for the EEG power in REM sleep also the power during non-REM sleep, which 
is characterized by high values in the delta frequency band (0.5–5 Hz), was unchanged 
between the two genotypes at the BL during the light and dark period (Figure 10D). After 
administering Pitolisant an increase in delta power was more apparent in the control 
mice, which reached significance in the range of 2–4.5 Hz when compared with mutant 
mice (p= < .0001, Figure 10D). Interestingly, although the PWScrm+/p- mice did not show a 
significant reduction of non-REM sleep during the dark period, as observed in the 
PWScrm+/p+ mice, however the latter showed a higher EEG power during non-REM sleep, 
which may be explained by a significant increase in the sleep fragmentation after 
Pitolisant administration in mutant mice. No differences were observed between the two 








Figure 10, Effect of Pitolisant on the Sleep-wake cycle 
 A) Wake-sleep distribution over an uninterrupted 48-hour period over a 12-hour light/dark cycle as baseline 
values and the following 24-hour after Pitolisant/vehicle treatment for control mice (left column in black line 
and grey and white dots for vehicle and Pitolisant treatment respectively) and mutant mice (right column in 
red line and pink and white dots for vehicle and Pitolisant treatment respectively) . Recordings were made 
with animals maintained at 22°C. Data are reported as the percentage in 2-hour bins, averaged within 
genotypes (mean ± SEM; n = 5 PWScrm+/p+ and n = 5 PWScrm+/p- mice for both conditions). B) The cumulative 
amount (mean ± SEM) of all sleep-wake stages during the 12-hour of the dark period (black bar above the 
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C) The normalized power density of the whole spectrum during REM sleep during baseline (left) and Pitolisant 
treatment (right) for both genotypes; red lines depict PWScrm+/p− mice, and black lines depict PWScrm+/p+ 
mice. D) The normalized power density of the whole spectrum during non-REM sleep during baseline (left) 
and Pitolisant treatment (right) for both genotypes; red lines depict PWScrm+/p− mice, and black lines depict 
PWScrm+/p+ mice. 
 
Finally, the DNE during sleep for the neck muscle was calculated, which is a marker of 
RSWA to evaluate whether mutant mice characterized by REM sleep alteration also 
presents RSWA, and also to evaluate the effect of Pitolisant on DNE in both mice lines 
[172], [173]. The whole distribution of the neck EMGnorm for PWScrm+/p+ mice who 
received placebo was higher during wakefulness and shifted downward during the two 
sleep stages, REM and non-REM, from the 75th to 99th centiles (p= .0002, Figure 11). The 
same distribution of the EMGnorm, as observed in the control mice was observed in the 
PWScrm+/p- mice which underwent placebo from the 50th to 99th centiles (p= .034, Figure 
11). Both genotypes at the BL showed the same distribution of EMGnorm as observed in 
the mice who received placebo (Figure S7B).  
Interestingly, after Pitolisant was administered the distribution of the EMGnorm during 
wakefulness and the two sleep stages did not differ in the PWScrm+/p+ mice, except for 
97th and 99th centiles (p= .0001, Figure 11). On the contrary, in the mutant mice 
significant differences in the EMGnorm between wakefulness and the two sleep stages 
(non-REM and REM sleep) was still observed from the 75th to 99th centiles (p= < .0001, 
Figure 11) after Pitolisant administration. Since in the control mice after Pitolisant 
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Figure 11, DNE 
Comparative physiology of muscle activity 
during sleep. The panels show the distributions 
of normalized electromyographic activity 
(EMGNORM) of neck muscles for PWScr
m+/p+ 
(left column) and PWScrm+/p- (right column) for 
both conditions, upper panel vehicle, lower 




may suggest that Pitolisant increases phasic or tonic muscle activity seen on 
polysomnographic electromyogram channels only in control mice and not in mutant mice.  
 
4.3.2 Effect of Pitolisant on physical activity 
Physical activity was assessed in awake mice, without any motor constraints, to determine 
whether Pitolisant is associated with side effects such as sedation and depression-like 
symptoms. Wild-type mice over the 24-hour of BL showed, as expected, an increase in 
physical activity during the night, while during the day their motility was reduced. In the 
same mice, Pitolisant did not modify the physical activity over the 24-hour compared to 
the previous BL (Figure 12). Conversely, in the mutant mice, an increase in physical activity 
was observed during the night (p. 006, Figure 12), in particular over the first 6-hour of the 
dark period (p= .002, Figure 12).  Interestingly, in the PWScrm+/p- mice after Pitolisant was 
administered physical activity was significantly reduced during the dark period decreasing 




Figure 12, Effect of Pitolisant on physical activity 
On the left, telemetry measurements of daily activity in home cages monitored 24-hour per day in 
PWScrm+/p+ (n= 10 in black) and PWScrm+/p- mice (n= 10 in red). With Pink and Gray are reported the two 
groups treated with the vehicle PWScrm+/p- and PWScrm+/p+ respectively. The black or red line of with dots 
represent the group treated with Pitolisant. On the right the spontaneous physical activity averaged during 
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Overall, the main results of this thesis reinforce the evidence that loss of Snord116 plays 
a crucial role in the regulation of REM sleep and thermoregulation, both phenotypes being 
dysregulated in PWScrm+/p- mutant mice and patients [100], [174]. In particular, we 
repeatedly observed REM sleep alterations in all studies performed in different 
experimental groups, at a particular time of the day when the pressure of sleep was 
increased [175], [176]; in mice, this occurs at a time in the sleep-wake cycle that 
corresponds to the “siesta time” [175], [176]. Moreover, we also observed that Snord116 
play a crucial role in the hypothalamic functions, primarily affecting the OX neurons. Next 
we observed that sleep spindle properties were found to be altered in the PWScrm+/p- 
mice, while their numbers were unchanged between the two genotypes, suggesting 
dysfunctions in the cortex where sleep spindles are amplified and not in the thalamus 
where they are generated. This data implies a dysfunction in the primary cortical neurons 
observed in PWScrm+/p- mice, reinforcing our results obtained on sleep spindles (The 
primary cortical neurons data refers to the MEA experiment, see the following link for 
more details https://doi.org/10.1101/809822).  
Taken together first two studies performed in this thesis strongly support that Snord116 
mouse model remarkably recapitulates all the sleep deficits of human PWS, but only 
incompletely mimics the metabolic alterations. Indeed, both PWS mice and human 
patients show an alteration of body weight, but the two species show opposite 
phenotypes; indeed, PWS patients exhibit increased body weight, while mouse models 
across different studies show reduced weight [99], [155], displaying at least only the first 
stage (Stage I) of the PWS clinical features, the infancy stage [101]. 
Finally, in the third part of this thesis we observed that Pitolisant ameliorates the REM 
sleep alteration in these mice, although other studies are needed to investigate whether 







5.1 The paternally imprinted gene Snord116 gene regulate hypothalamic orexin 
neurons, Study I 
In the Study I, we reported for the first time a lack of neuromodulation of the LH in 
Snord116 mutant mice, which is accompanied by an imbalance between OX and MCH 
neurons, causing a 60% reduction in OX neurons in the LH. Within the same 15q11-q13 
region, it was previously reported that Magel2 KO mice lose 40% of OX neurons [177]. 
These results suggest that multiple paternally expressed genes within the PWS region 
regulate the OX system in the LH, most likely in a dose-dependent manner. At baseline, 
we observed that fire discharge of neurons associated with sleep (i.e., S-max neurons) are 
higher in mutant mice than in controls, suggesting that the role of Snord116 that 
originates from the LH is important in the determination of abnormal sleep in PWS. 
Indeed, several lines of evidence indicate that LH exerts pivotal control of cortical sleep, 
including REM sleep [178]. Furthermore, while we observed that the proportion of S-max 
and W-max neurons significantly changed after 6-hour of SD with an increase in sleep 
neurons of approximately 13% in wild-type control mice, PWS mutants lack this neuronal 
response by the LH to sleep loss. In the LH, OX and MCH systems exert opposing effects 
on REM sleep [179]: OX suppresses while MCH promotes REM sleep. Therefore, the 
imbalance between OX and MCH systems in PWS mutants is in agreement with an 
increase in REM sleep. 
Additionally, OX and MCH neurons in the LH regulate food intake and metabolism [180], 
[181]. We found that mutant mice displayed a higher proportion of neurons, which were 
classified as non-responding neurons (type III), relative to food intake than controls. In 
contrast, type II neurons, which are downregulated in the LH during eating, were 
significantly reduced in mutants. It has been demonstrated that OX neurons decrease 
their firing during eating and remain in a depressed state throughout the entire eating 
phase [182]. These findings suggest a lack of regulatory feedback mechanisms mediated 
by the OX system in relation to food intake in the LH of PWS model mice, a phenomenon 
that can relate to the hyperphagia and obesity phenotype observed in PWS patients. This 
evidence of neuromodulatory dysregulation of the LH is in agreement with previous 
results [154], which describe that a late onset of mild hyperphagia and obesity in mice can 




Dysregulation of the OX system has been reported in a few clinical studies, although to 
date, the results remain contradictory. One study described an increase in the OX-A level 
in PWS subjects [183], while another showed a decrease in the peptide in the 
cerebrospinal fluid [184]. Taken together, these findings call for an alteration of the OX 
system in PWS, although the contrasting results may also suggest that the loss of function 
of paternal alleles within the PWS region results in an increased phenotypic variance. 
These data suggest that Snord116 is essential for the regulation, formation and 
maintenance of the OX system in the LH. We assessed Snord116 expression in two 
different strains with OX deficiency, OX/ataxin-3 (Atx) mice and OX peptide knockout (KO) 
mice [130], [168], and we found that only Atx mice showed a significant increase in 
Snord116. This line selectively loses OX neurons and their co-transmitters. In contrast, in 
KO mice that do not display a loss of OX neurons but are lacking OX peptides, the level of 
Snord116 was unaffected. The increase in Snord116 in mice with depletion of OX neurons 
is probably a compensatory mechanism. My conclusions are supported by a recent study 
[164] that described the role of Peg3 in the development and expression of OX and MCH 
neurons. The study demonstrates for the first time that PEG3 is able to bind OX promotors 
by increasing the expression of OX. However, a reduced binding of PEG3 was observed in 
mutant mice relative to control mice, which may be explained by a reduction in OX 
neurons. Thus, Peg3 was selectively altered in PWScrm+/p- mutant mice as well as in 
narcoleptic mice. In particular, Peg3 was found to be altered only in Atx narcoleptic mice, 
while it was unchanged in Ppox KO mice. This may be explained by the fact that PEG3 
binds the OX promoter, which is not altered in KO mice because they have a null mutation. 
This study reveals that these two paternally imprinted genes, Snord116 and Peg3, are 
unlikely to interact with each other, but both contribute to the development and 
functions of OX neurons. Indeed, in our in vitro experiment with immortalized 
hypothalamic cells, knockdown of Snord116 did not change the levels of Peg3. 
All these evidences are in line with the pioneering evidence in androgenetic mice [125] 
that paternally imprinted genes are important for the formation of the hypothalamus. In 
particular, this study implies that Snord116 and Peg3 plays a crucial role in the formation 
of OX neurons. 
We observed that PWScrm+/p- mutant mice present a high body temperature coupled with 




tightly integrated with the regulation of sleep and is also controlled by OX 
neuromodulation [169], [185]. For example, narcoleptic subjects exhibit a paradoxical 
lower core body temperature while awake [186] and a higher body temperature during 
sleep [187], [188]. In mammals, in physiological conditions, peripheral vasodilatation 
helps decrease the core body temperature during sleep initiation. Mutant mice displayed 
a high body temperature during the light period, which corresponded to their resting 
phase/subjective sleep. Interestingly, narcoleptic mice show body similar temperature 
abnormalities [189]. Moreover, when PWS mutant mice were kept at the TNZ, where 
resting metabolic rate remains stable and where REM sleep is preferentially increased 
[190], [191], we observed a surprising thermoregulatory response coupled with an altered 
homeostatic REM sleep response. REM sleep did not increase, and the peripheral 
thermoregulatory response of the mutant mice resembled what would be expected in a 
sub-neutrality (e.g., 22°C) environment. REM sleep is a stage of sleep in which 
thermoregulation is suspended; for this reason, REM sleep expression is more sensitive 
to ambient temperature manipulation than non-REM sleep [190], [191].  
A recent study [192] described that endotherms have evolved neural circuits to 
opportunistically promote REM sleep when the need for thermoregulatory defense is 
minimized, such as in TNZ conditions, suggesting a tight link between thermoregulation 
and REM sleep. In this study, the increase in body weight observed at the TNZ suggests 
that thermoneutrality is a permissive condition that induces body weight gain but does 
not compensate for the metabolic abnormality in these mice. Indeed, the differences with 
wild-type mice remained unchanged. Mutants showed growth retardation at both 
environmental conditions investigated, namely, at both 22°C and 30°C. 
 
The transcriptomic analysis in the hypothalamus suggests that loss of Snord116 might 
negatively affect synaptic organization while promoting inflammatory responses in the 
hypothalamus, as previously observed in post-mortem hypothalamic brain tissue from 
PWS patients [160] . GO analysis of all 833 DEGs in the mutant hypothalamus following 
SD suggested, instead, that loss of Snord116 leads to a homeostatic response that relies 
on several cellular growth processes of the hypothalamus (Figure 5E). This result indicates 
that defects in sleep homeostasis in PWS can be derived from development processes of 




[195]. This data has a clinical implication because up to 76% of PWS patients exhibit 
abnormal and poor sleep [8], [196] that may negatively impact the normal function of the 
hypothalamus. 
In conclusion, this study demonstrates for the first time that paternally expressed genetic 
elements in the LH affect the dynamics between neuronal activity in the LH and cortical 
EEG sleep states. This new evidence reinforces the recent hypothesis that genomic 
imprinting plays a crucial role in mammalian sleep [197] and confirms original studies in 
androgenetic chimeric mice [125], suggesting that the paternal genome may account for 
regulatory mechanisms in the hypothalamus. 
 
5.2 The paternally imprinted gene Snord116 regulates macrostructural sleep 
aspects and cortical neuronal activity, Study II 
In the Study I, we observed that mice lacking the Snord116 had an increase in REM sleep 
during the dark period, when mice are most active, and may resemble the EDS observed 
in humans PWS [108]. Since it has already been reported that REM sleep is precisely 
regulated in terms of its duration, while non-REM is substantially regulated in terms of 
intensity [36], [157], we decided in the study to analyze the succession of REM sleep 
episodes and the period of time intervening between the end of one REM sleep episode 
and the beginning of the next (REM sleep interval, RSI). RSI follows a bimodal distribution 
characterized by short and long periods. The presence of a bimodal distribution has 
already been described [156] in many species, such as rats [198], cats [199] and humans 
[200], but, at the best of my knowledge, no data are yet available on the RSI distribution 
in mice. For the first time, these data reveal a bimodal RSI distribution in mice, with the 
minimum frequency at 55 sec, while in rats, the minimum between the two peaks has 
been identified at 3 min [156]. A bimodal distribution of RSI was observed in both 
genotypes of mice. However, mutant mice showed a significant increase in short RSI. 
Short RSI has been described as an indicator of the capacity to produce REM sleep in 
accordance to the homeostatic drive under favorable ambient conditions and associated 
with the capacity to produce REM sleep proportionally to the homeostatic drive under 
favorable ambient conditions [156], [201]. Indeed, the amount of REM sleep with short 




I. to be increased during a REM sleep rebound in proportion to the degree of 
previous REM deprivation induced by low ambient temperature [147]; 
II. to be depressed when animals are kept under an uncomfortable ambient 
condition, such as during the exposure to a low Ta [156], and concomitantly with 
a reduced capacity of cAMP accumulation at hypothalamic-preoptic level [202], 
[203].  
 
This observation may reflect a strengthened drive for REM sleep and/or a distorted and 
more favorable perception of the ambient conditions, in terms of the thermal comfort, in 
the mutant mice. Therefore, since sleep propensity also affects the non-REM-REM cycle, 
I also assessed the number of these cycles over the 24-hour of the BL in both genotypes 
of mice. As expected, mutant mice presented a significant increase in the non-REM-REM 
cycle (approximately 2-5 minutes) [148] compared to the control group, suggesting, once 
again, that the mutant mice have a strong tendency to fall asleep easily. Overall, these 
data imply that the loss of Snord116 significantly compromised sleep microstructure, 
mainly affecting REM sleep.  
We found that PWScrm+/p- mice showed alterations in REM sleep without affecting non-
REM sleep. An exception, however, was found in the sleep spindles, hallmarks of non-
REM sleep that reflect the activity of complementary thalamocortical circuits. The 
thalamic reticular nucleus (TRN) is the spindle pacemaker, and TRN/thalamus circuits can 
generate spindles in isolation, although cortical inputs may contribute by initiating or 
amplifying spindle oscillations [71], [72].  Here, we show that the duration, amplitude and 
frequency of sleep spindles are significantly altered in PWScrm+/p- mice, while their 
numbers are unchanged between the two genotypes. This data suggests that 
TRN/thalamus circuits or in corticothalamic afferents to these intra-thalamic circuits may 
probably not affected in the mutant mice, while, an impairment of cortical amplification 
may explain the alterations of sleep spindles properties. Since it has been shown that 
sleep spindles facilitate neuroplasticity and support learning, memory consolidation, and 
intellectual performance [204], and since sleep spindle alterations have been 
documented in children with neurodevelopmental disorders [204], [205], I speculate that 
the neurodevelopmental and cognitive alterations observed in these mice [206] may also 




either reflect the severity of the underlying disorder or directly exacerbate the severity of 
impairments. Evidence also indicates that alterations in sleep spindle properties have a 
very early association with an increased risk of cognitive impairment [207]; These results 
imply that sleep spindles may also represent reliable sleep EEG biomarkers associated 
with PWS disorder, although a better characterization of these findings in PWS subjects is 
needed. 
Additionally, we observed that PWScrm+/p- mice have dysregulated norepinephrine levels 
in the CSF collected at the beginning of the dark period. Norepinephrine is a 
neurotransmitter important for maintaining normal sleep states, and dysregulated 
norepinephrine signaling is responsible for cataplexy attacks, which, together with 
narcolepsy, represent common features of PWS [208].  
Thus, the activity of norepinephrine neurons in the locus coeruleus is important in 
modulating cortical activity during non-REM sleep [209]. Norepinephrine not only 
influences general arousal but also affects locomotor activity. Indeed, it has been 
observed that intraventricular infusion of norepinephrine increases motor activity [210]. 
Interestingly, we observed that norepinephrine was significantly higher in the mutant 
mice than in the controls, suggesting that norepinephrine may also have a role in 
controlling motor activity in these mice. Overall, these data imply that mutant mice may 
also have a dysregulated norepinephrine system. The extent to which norepinephrine 
alterations may affect the sleep-wake cycle and locomotor activity should be further 
investigated and may have therapeutic relevance.  
These data imply a dysfunction of cortical amplification, manifested by the altered sleep 
spindles properties not affecting their numbers observed in the mutant mice. Based on 
these results, we investigated whether cortical neurons isolated from thalamocortical 
projections showed an altered intrinsic mechanism of sleep comparable to the sleep 
endophenotypes observed in living mice. To address this question, I worked in 
collaboration with Ilaria Colombi on her doctoral project, for the results see link 
https://doi.org/10.1101/809822. There we used an in vitro model. Previous studies have 
demonstrated that embryonic cortical neurons on MEA are able to recapitulate some 
essential features of sleep in a controllable way [211]–[213]. Here, we treated cortical 
cultures with Carbachol to change the synchronized default sleep-like state, characterized 




is typical of REM sleep. Because of this EEG feature of REM, the shorthand definition of 
REM sleep is a highly activated brain in a paralyzed body [214]. The LFP analysis of MEA 
cortical neurons revealed abnormalities in the theta waves in the PWScrm+/p- neurons 
similar to those observed in living mice. Carbachol administration caused evident 
desynchronization of the activity of both genotypes, but mutant cultures showed different 
response profiles after Carbachol treatment compared to control cultures. Overall, these 
results suggested that PWS cultures displayed alterations in neuronal activity patterns 
during spontaneous activity and when external stimulation was applied. Taken together, 
these data imply that Snord116 may either directly influence the neuronal 
synchronization of cortical neurons or affect it indirectly via norepinephrine, which we 
found to be altered in our study in living mice. Indeed, norepinephrine is a 
neurotransmitter that decreases network synchrony both in vivo [215], [216] and in vitro 
[215], consistent with our results, in which PWScrm+/p- cultures showed an increased level 
of this neurotransmitter that may be responsible for the increased desynchronization 
level of activity in the MEA recording. 
Finally, we also assessed the expression of IEGs in both in vitro and in vivo models, and 
we observed that our in vitro model exactly recapitulates the transcriptional alteration 
observed in living mice. This finding also suggests that cortical cultures coupled to MEA 
represent a promising tool to identify novel therapeutic targets, such as sleep feature 
alterations and network synchronization defects. Moreover, these data suggest, in 
agreement with a recent publication [217], that the Snord116 gene affects the 
transcriptional profiles of circadian genes in the cortex (Per2 and Bmal1), which are 
involved in development outside the suprachiasmatic nucleus and contribute to brain 
plasticity [218]. Indeed, we also found that the PWScrm+/p- mice had low levels of Bdnf 
mRNA, which is extremely important in the regulation of synapses and the plasticity 
process. This latter evidence may pave the way for new interventional approaches for 
PWS by using TrkB agonists or by using compounds that increase the BDNF level [219]. 
Overall, the results suggest once again that Snord116 is important in controlling REM 
sleep. Additionally, here I provide the first evidence supporting the role of Snord116 in 
regulating cortical neuronal activity, opening avenues for new interventions in PWS. The 
dysregulation of sleep spindles in mutant mice raises the possibility that this phenomenon 





5.3 Effect of Pitolisant on REM sleep alteration in the Snord116 mice as model of 
Prader Willi Syndrome, Study III 
In the Study I and II, we systematically observed that mice carrying the paternal deletion 
of the Snord116 gene have a REM sleep alteration, supporting the hypothesis that REM 
sleep, its propensity and regulation is linked to genomic imprinting [197]. Additionally, the 
Study I describe that paternally expressed imprinted genes are essential for hypothalamic 
function, in regulating the homeostatic and circadian sleep process. This process may be 
mediated via the regulation of orexin levels, which was found significantly reduced in 
these mice. Based on this latter evidence we decided to administer Pitolisant to 
PWScrm+/p- mice, with the aim of ameliorating the sleep phenotypes. Pitolisant, is a wake 
promoting drug that enhances wakefulness by acting not only on the histaminergic 
system, which should not be compromised in these mice, but also by modulating other 
ascending waking pathways [131]. 
Overall these data shows that the control mice adequately respond to Pitolisant by 
increasing wakefulness and reducing total sleep, with both non-REM and REM sleep 
stages being decreased, during the dark period, immediately after administration. 
Conversely, the response of Pitolisant in mutant mice was much less marked. Indeed, 
mutant mice after being administered Pitolisant did not show a significant change in 
wakefulness, total sleep and non-REM sleep during the 12-hour of the dark period 
compared to PWScrm+/p- mice who received a placebo.  This suggests a high propensity to 
sleep and an inability to maintain wakefulness in these mice. Interestingly, we observed 
that the only stage of sleep significantly affected by Pitolisanat in the mutant mice was 
the REM sleep, which was significantly reduced after its administration during the night.  
This reduction of REM sleep is fully recovered over the following day in the mutant mice, 
while in the control group REM sleep was still reduced, suggesting a higher propensity in 
these mice to enter into REM sleep.  
Overall this data highlights that Pitolisant ameliorates the REM sleep alteration in these 
mice, although other studies are needed to investigate whether Pitolisant may also 






5.4 Limitations of the thesis and suggestions for future experiment 
Although in this thesis several methodological approaches have been used to understand 
the role of the Snord116 gene in the regulation of the hypothalamus and sleep functions 
in these mutant mice, I believe that two crucial experiments are needed to clarify whether 
Snord116 may recapitulate some of the endophenotypes observed in the mutant mice 
and discussed in this study. 
Specifically, could be interesting to clarify the effect of: 
I. Snord116 deletion in specific neurons versus the KO deletion affecting all brain;  
II. Snord116 congenital deletion versus deletion induced in adult mice.  
 
In this thesis, we showed that mice lacking the Snord116 in the whole brain has REM sleep 
alteration and OX dysfunction. However, would be extremely interesting to know whether 
the conditional deletion of the Snord116 gene in specific cell/neuron (i.e Orexin) could be 
enough to recapitulate the alteration observed in these mutant mice. To perform this 
experiment, I should have used transgenic line mice that drive Cre-gene expression under 
the control of the OX promotor (OXcre/+). Specifically, these mutant mice PWScrm+/p- should 
be crossed with a transgenic OXcre/+ mouse to generate double heterozygous mice 
(PWScrm+/p-/OXcre/+).  
Next, it could be useful to understand whether the deletion of the Snord116 induced in 
adult mice may negatively affect the orexin neurons.  This experiment may help to 
understand the role of the Snord116 in the neurodevelopmental deficit affecting the used 
mutant mice and described by several research groups [220] that is something beyond 
the reduction of the OX neurons. Thus, may help to clarify whether Snord116 is extremely 
important for the formation maintenance and regulation of the OX neurons, as I 
hypothesized in the study I or rather is related to the neurodevelopmental deficit affecting 
these mice. This study should have been performed by using transgenic OXcre/+ mice 
where Snord116 should be selectively KO in the LH by using a specific siRNA for Snord116 








Overall in all three studies I observed that Snord116 play a crucial role in the regulation of 
REM sleep and its propensity and for the fine regulatory cortical process that controls 
sleep architecture. The REM sleep alterations may be compatible with a loss of OX-
expressing neurons in the LH, while MCH-expressing neurons remained unaffected, 
thereby creating an imbalance between the two systems. I also report, for the first time, 
a link between Snord116 and a different paternally imprinted gene, Peg3, which plays a 
pivotal role in the control of the hypothalamic OX neuromodulator system. Finally, here I 
also provide a new pharmacological approach for PWS to ameliorate the sleep alteration 
that significantly affect the PWS patients, although clinical trials are needed to confirm 
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INTRODUCTION
Behavior is a noisy phenomenon to study in animal models. The 
resultant difficulty in investigating behavior is coupled with the 
limitations of traditional behavioral phenotyping procedures in 
mice, which are often inefficient (low-throughput) and can lead to 
inconsistent results. Disparate behavioral findings from ‘identical 
assays’ caused by exogenous factors have been demonstrated by 
cross-laboratory studies in different mouse strains and mutants, 
suggesting that findings regarding many behavioral measures may 
in fact be specific to individual laboratories. For instance, despite 
all the efforts to equate the testing conditions among three differ-
ent testing sites and cocaine-induced locomotor activity, as well as 
activity and the time spent in open arms of an elevated plus maze 
(as an index of anxiety), results differed between sites1.
Nevertheless, the investigation and characterization of behavior 
remain a fundamental part of the analysis of many biological sys-
tems and, therefore, are of great interest to the life sciences. Mouse 
is a widely used animal model, not only to map mammalian genes, 
but also to determine the function of each of these genes, includ-
ing its association with behavioral and cognitive traits. There are 
now several large-scale projects creating collections of mutant 
mice for the study of ~20,000 mouse genes. All these projects are 
rigorously producing extensive archives of mouse lines, which 
are available for use by the wider scientific community. However, 
behavioral phenotyping with traditional methods constitutes a 
limiting factor in the evaluation of these lines due to their low-
throughput and the data not being suitable for computational 
analytical approaches. For instance, the Morris water maze, which 
is typically used to test spatial memory performance, requires 
the testing of animals out of the cage over multiple trials and 
sessions (i.e., days). The critical unit of analysis in this task is the 
latency to locate a hidden platform upon the placement of the 
animal in a circular pool by the experimenter, which is not ideal 
for modeling the data for elucidating the generative processes 
that underlie performance. Consequently, the next critical step 
that would add substantial value to the field is the annotation of 
precise phenotypes for each of these models.
To capture the complexity of mouse behavior, neurogeneticists 
adopt a reductionist strategy, focusing on intermediate pheno-
types (endophenotypes).
Conventionally, endophenotypes have been conceptualized as 
heritable behavioral symptoms that can be measured in affected 
and unaffected subjects in order to identify the genes linked to a 
given disease2–4. The so-called ‘dissecting complex phenotypes’ 
model5 has been extensively adopted in translational research 
because it reduces the burden of analyzing intricate behaviors, 
which are often difficult to define and parameterize in animal 
models. This approach has partially shifted interest in genetic 
psychiatry from targeting psychiatric diseases as a whole toward 
mapping the genetic basis of the endophenotypes that independ-
ently characterize the symptomology of the psychiatric diseases. 
It is believed that the complexity of phenotypes depends on the 
complexity of the underlying genetics. As a consequence, in 
experimental practice, it is assumed that by reducing the com-
plexity of the targeted phenotypes, a smaller genetic network will 
be captured and this will progressively lead to the identification 
of individual readouts of the isolated single genes.
The effect size observed in relation to a given endophenotype 
serves as an operational measure of the phenotypic variance 
associated with a genetic locus3; hence, it is informative of the risk 
of disease manifestation. For example, specific genetic variants 
within the 22q11.2 region, coding for the enzyme catechol 
O-methyltransferase (COMT), which is fundamental for the 
catabolism of dopamine, are widely studied to account for a range 
of behavioral and physiological endophenotypes that depend 
on the function of the prefrontal cortex, as well as occurring in 
combination with schizophrenia6–8. Interestingly, meta-analyses 
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Genetically modified mice are used as models for a variety of human behavioral conditions. However, behavioral phenotyping can 
be a major bottleneck in mouse genetics because many of the classic protocols are too long and/or are vulnerable to unaccountable 
sources of variance, leading to inconsistent results between centers. We developed a home-cage approach using a Chora feeder 
that is controlled by—and sends data to—software. In this approach, mice are tested in the standard cages in which they are held 
for husbandry, which removes confounding variables such as the stress induced by out-of-cage testing. This system increases the 
throughput of data gathering from individual animals and facilitates data mining by offering new opportunities for multimodal 
data comparisons. In this protocol, we use a simple work-for-food testing strategy as an example application, but the approach 
can be adapted for other experiments looking at, e.g., attention, decision-making or memory. The spontaneous behavioral activity 
of mice in performing the behavioral task can be monitored 24 h a day for several days, providing an integrated assessment of 
the circadian profiles of different behaviors. We developed a Python-based open-source analytical platform (Phenopy) that is 
accessible to scientists with no programming background and can be used to design and control such experiments, as well as to 
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Supplementary 1 A) Whit blue bar are reported the frequency distribution of the duration of the interval 
from the end to one REM sleep episodes to the beginning of the subsequent episodes (REM sleep interval, 
RSI) during light dark cycle in mice. The grey line is the kernel density estimation constructed with the 
distribution of the REM sleep episodes. The green line is the smoothing of the grey line using the Savitzky-
Golay Filter. 
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Supplementary 2, PWScrm+/p− mice have altered neuronal dynamics of the LH in relation to sleep and food. 
The results of single unit activity (SUA) combined with EEM/EMG recordings. A) The percentage of total time 
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compared with control mice (black bar). EEG/EMG/SUA were recorded at different time points and are 
shown in each row: B1 and B2, baseline; SD1, 1-h immediately after 6 h of SD; and SD2 and SD3, two time 
points during the 18-h recovery period. At B1, REM sleep was increased in PWScrm+/p− mice (unpaired t-test: 
t(6) = 3.06, p = .02) relative to PWScrm+/p+ mice. At B2, no differences between the two genotypes were 
observed in any of the sleep stages investigated. At SD1, total sleep was increased in PWScrm+/p− mice 
(unpaired t-test: t(6) = 3.53, p = .01) relative to controls. At SD2, no differences between the two genotypes 
were observed in any of the sleep stages investigated. At SD3, total sleep (unpaired t-test: t(6) = 2.52, p = 
.04) and NREM sleep (unpaired t-test: t(6) = 2.64, p = .03) were decreased in PWScrm+/p− mice relative to 
PWScrm+/p+ mice. Data are presented as the mean ± SEM. Asterisks (*) indicate a significant difference 
between genotypes: * P ≤ .05. B) The panel shows the neuronal distribution of recorded neurons (according 
to the classification described in the Methods session) in a pie chart for each time point. The percentage is 
derived from the total number of recorded neurons.  W-max neurons are shown in green, S-max neurons are 
shown in blue, and ws neurons are shown in yellow. Differences between the two genotypes are indicated 
by $, while differences within groups across time points are indicated by §. Significance was computed with 
the chi-square test. C) The normalized power density of the whole spectrum during NREM and REM sleep 
(left and right, respectively) for both genotypes; red circles depict PWScrm+/p− mice, and black circles depict 
PWScrm+/p+ mice. D) Neuronal classification in a 2D scatter plot. The x-axis plots the mean firing rate of each 
cell in the state in which they maximally fire, and the y-axis plots the mean logarithm of EMG signals 
according to the selected sleep-wake state. W-max neurons are shown in green, S-max neurons in blue, and 
ws neurons in yellow. Neurons recorded from mutant mice are marked by red dots. Putative OX neurons 
(green squares) and MCH putative neurons (blue squares) are also shown (see Methods). The two genotypes 







Supplementary 3, Sleep-wake cycle and temperature profile recorded. A) The panel shows the hourly 
percentage of time spent in wakefulness, total sleep (including both NREM sleep and REM sleep), NREM 
sleep, and REM sleep in PWScrm+/p− mice (red) versus control mice (black), recorded over an uninterrupted 
24-h period of the 12-h light/dark cycle for baseline (BL) and during the 18-h after SD. Recordings were 
conducted in animals maintained at 22°C (cyan bar in each graph) and at 30°C (orange bar in each graph). 
No significant differences were found at 22°C between genotypes among all sleep stages investigated. At 
30° C, a two-way repeated-measures ANOVA revealed significant main effects of time for wakefulness 
(F(11,88) = 13.70, p < .0001 “time”), for total sleep (F(11,88) = 13.51, p < .0001 “time”) and for NREM sleep 
(F(11,88)= 12.50, p = <.0001 “time”). Data are presented as the 2-h mean values ± SEM. B) Cumulative 
amount of time spent in wakefulness, total sleep and NREM sleep for PWScrm+/p− and PWScrm+/p+ mice over 
the 12-h light period and the 12-h dark period. Cyan bar indicates the baseline (BL) value, the white bar 
indicates the 18-h recovery (RB) period following 6 h of SD, and the orange bar indicates recordings at 30°C. 
Statistical analysis was performed by one-way ANOVA followed by post hoc analysis with the Bonferroni 
multiple comparison test. Dark period: PWScrm+/p+ mice showed a difference in the percentage of 
wakefulness (F(1.79, 7.19)= 6.85, p = .02), total sleep (F(1.80, 7.20)= 7.35, p = .01) and NREM sleep (F(1.86, 
7.46)= 5.40, p = .03). Data are presented as the mean ± SEM. Asterisks (*) indicate a significant difference 
between genotypes: * P ≤ .05. C-D) Spectral analysis. Normalized delta and theta power during NREM sleep 
(C-upper) and REM sleep (D-upper) at 22°C (cyan bar above the graph) and at 30°C (orange bar above the 
graph) and after SD and relative to baseline for PWScrm+/p− mice (D-button) were recorded between 
genotypes. No substantial differences were observed between genotypes and conditions investigated. Data 
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genotypes: * P ≤ .05; **p ≤ .01; *** p ≤ .001; **** p ≤ .0001. The bottom right shows the normalised theta 
power recorded from ZT 6 to ZT 10, and no differences were observed between genotypes. Two genotypes 
were investigated: PWScrm+/p− mice (n= 10, 5 mice at 22°C and 5 mice at 30°C) and PWScrm+/p+ mice (n= 10, 
5 mice at 22°C and 5 mice at 30°C). E) Head temperature (Head-T) profiles for PWScrm+/p+ and PWScrm+/p- 
mice were recorded with an infrared thermocamera over 24 h. Recordings were performed under two 
different environmental conditions: at 22°C (cyan bar over the graph, shown on the left) and at 30°C, 
representing the thermoneutrality zone (TNZ) (orange bar over the graph, shown on the right). T-head was 
slightly increased in PWScrm+/p- mice relative to control mice during the dark period at ZT 14 at 22°C. Asterisks 
(*) indicate a significant difference between genotypes: * P ≤ .05. 
 
 
Supplementary 4, Snord116 loss induces growth retardation. Body weight was assessed at 22°C and 30°C 
(TNZ). A) The absolute weekly body weights of mice born at 22°C (cyan connection) and mice born at 30°C 
(orange connection) were assessed. PWScrm+/p− mice are indicated by red circles, while PWScrm+/p+ mice are 
represented by black circles. Two-way ANOVA revealed that PWScrm+/p− mice had significant growth 
retardation compared with control mice when raised at either 22°C or 30°C (F(3, 32)= 179.5, p = < .0001 
“time”; F(3, 32)= 45.07, p = < .0001 “genotypes”). a indicates differences between genotypes at 22°C, while 
b indicates differences between genotypes at 30°C. Two genotypes were investigated: PWScrm+/p− mice (n= 
10, 5 mice at 22°C and 5 mice at 30°C) and PWScrm+/p+ mice (n= 10, 5 mice at 22°C and 5 mice at 30°C). B) At 
15 to 20 weeks of age (at the time point when the sleep-wake cycle was recorded), the absolute weekly body 
weight was assessed in mice after housing for 5 weeks either at 22°C or 30°C. Two-way ANOVA revealed 
that PWScrm+/p− mice had significant growth retardation compared with control mice housed at either 22°C 
or 30°C (F(3, 32)= 10.58, p = < .0001 “interaction”). a indicates differences between genotypes at 22°C, while 
b indicates differences between genotypes at 30°C. Two genotypes were investigated: PWScrm+/p− mice (n= 
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Supplementary 5, Gene expression analysis of the OX amd MCH systems. A) Experimental timeline. 
PWScrm+/p− and PWScrm+/p+ mice were sacrificed at three different time points to assess the gene expression 
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6-h of SD at ZT 6 (T1), and after 6-h of SD (ZT 7; T2). B) At T1, PWScrm+/p− mice showed reduced Ppox (unpaired 
t-test: t(8) = 3.14, p = .01) and Pmch (unpaired t-test: t(8) = 2.66, p = .02) compared with PWScrm+/p+ mice. 
At T2, no differences were observed between the two genotypes for both genes. C) Gene expression analysis 
of the OX receptor 1 (Ox1R), the OX receptor 2 (Ox2R) and the MCH receptor 1 (Mch1R) in the hypothalamus 
(Hy), the frontal cortex (FC) and the parietal cortex (PC). The green lines in T1 and T2 represent the baseline 
value (T0). Only OxR2 in the PC was found to be increased in PWScrm+/p− mice (unpaired t-test: t(8) = 3.44, p 
= .008). Gene expression (mean ± SEM) was assessed by qRT-PCR in mice of the 2 genotypes: PWScrm+/p− 
mice (n= 15, 5 mice for each time point) and PWScrm+/p+ mice (n= 15, 5 mice for each time point). Gapdh was 
used as a reference gene. 
 
 
Supplementary 6, Gene expression analysis of the maternally and paternally imprinted genes in PWScrm+/p− 
mice and in mice of two narcoleptic models. A) Gene expression analysis of Peg1, Peg12, Snurp Magel2 
Meg3 and Ube3a in PWScrm+/p− mice relative to control mice. Unpaired t tests did not reveal any significant 
changes between the two genotypes. B) Gene expression of Peg1, Peg12, Snurp Magel2 Meg3 and Ube3a in 
WT, KO and Atx mice. One-way ANOVA did not reveal any significant changes between genotypes. C) Gene 
expression analysis of Ppox, OxR1, OxR2, Pmch and MchR1 in WT, KO and Atx mice. We confirmed a 
significant reduction in Ppox in both strains of narcoleptic mice relative to WT mice (one-way ANOVA: 
F(3,16)= 11.63, Bonferroni post hoc test p = <.0001). OxR1 (one-way ANOVA: F(3,16)= 7.034, Bonferroni post 
hoc test p = <.03) and MchR1 (one-way ANOVA: F(2,15)= 5.17, Bonferroni post hoc test p = <.01) were 




PCR in mice of the 2 genotypes: PWScrm+/p− mice (n= 5) and PWScrm+/p+ mice (n=5). KO (n= 12) and Atx (n=4) 
narcoleptic mice were investigated and compared with WT mice (n=4). Gapdh was used as a reference gene. 
D) Gene expression analysis of Pmch and Snurp in the Snord116-siRNA-treated immortalised hypothalamic 
rat cell line (green bars). Both genes were unchanged compared with untreated cells or scrambled siRNA-
treated cells (white and orange bars). E) ChIP analysis of PEG3 binding on the Gapdh promoter region in 
PWScrm+/p− mice (red) versus controls (black). Values are expressed as the mean of the input ± standard 
deviation. F) A cartoon showing the details and coordinates of the genomic region assessed in the ChIP 
analysis of PEG3 binding to the Ppox promoter region. 
 
 
Supplementary 7, A) The normalized power density of the whole spectrum during non-REM and REM sleep 
(top and button, respectively) for both genotypes in two conditions (vehicle on the left column, Pitolisant on 
the right column); red lines depict PWScrm+/p− mice, and black lines depict PWScrm+/p+ mice; white dots are 
for the Pitolisant treatment while grey are for the vehicle. B) Comparative physiology of muscle activity 
during sleep. The panels show the distributions of normalized electromyographic activity (EMGNORM) of 
neck muscles for PWScrm+/p+ (top) and PWScrm+/p- (button) for both conditions, left panel vehicle, right  panel 
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Supplementary Table 1: Imprinted gene 
See attached excel file 1 
 
Supplementary Table 4: RNA sequencing 
See attached excel file 2 
 
 






















B1 B2 SD SD1 SD2 
m+/p+ m+/p- m+/p+ m+/p- m+/p+ m+/p- m+/p+ m+/p- m+/p+ m+/p- 
W-max 90 60 104 43 48 55 77 73 96 54 
Wake  
NR - max 2 21 1 19 6 27 6 17 24 23 
R - max 2 4 2 4 2 17 5 5 2 11 
NRR - max 1 5 3 7 15 3 1 9 1 12 
Sleep  
wsp 9 11 1 9 14 11 13 5 4 16 
WR - max 3 4 6 6 31 8 0 4 0 5 
None  




Genotype: m+/p+ m+/p- 
W-max 415 285 
Wake 
NR - max 39 107 
R - max 13 41 
NRR - max 21 36 
Sleep 
wsp 41 52 
WR - max 40 27 
None 
Total 569 548 
 
B1 m+/p+ m+/p- Totals m+/p+ m+/p- Totals m+/p+ m+/p- Totals
W-Max 90 60 150 S-max 5 30 35 ws 12 15 27
Others 17 45 62 Others 102 75 177 Others 95 90 185
Totals 107 105 212 Totals 107 105 212 Totals 107 105 212
p-value <.0001 p-value <.0001 p-value ns
B2 m+/p+ m+/p- Totals m+/p+ m+/p- Totals m+/p+ m+/p- Totals
W-Max 104 43 147 S-max 6 30 36 ws 7 15 22
Others 13 45 58 Others 111 58 169 Others 110 73 183
Totals 117 88 205 Totals 117 88 205 Totals 117 88 205
p-value <.0001 p-value <.0001 p-value .02
SD m+/p+ m+/p- Totals m+/p+ m+/p- Totals m+/p+ m+/p- Totals
W-Max 48 55 103 S-max 23 47 70 ws 45 19 64
Others 68 66 134 Others 93 74 167 Others 71 102 173
Totals 116 121 237 Totals 116 121 237 Totals 116 121 237
p-value ns p-value .0017 p-value <.0001
SD1 m+/p+ m+/p- Totals m+/p+ m+/p- Totals m+/p+ m+/p- Totals
W-Max 77 73 150 S-max 12 31 43 ws 13 9 22
Others 25 40 65 Others 90 82 172 Others 89 104 193
Totals 102 113 215 Totals 102 113 215 Totals 102 113 215
p-value ns p-value .059 p-value ns
SD2 m+/p+ m+/p- Totals m+/p+ m+/p- Totals m+/p+ m+/p- Totals
W-Max 96 54 150 S-max 27 46 73 ws 4 21 25
Others 31 67 98 Others 100 75 175 Others 123 100 223
Totals 127 121 248 Totals 127 121 248 Totals 127 121 248
p-value <.0001 p-value .052 p-value .0002
m+/p+ B1 B2 Totals m+/p- B1 B2 Totals
ws 12 7 19 ws 15 15 30
W-max 90 104 194 W-max 60 43 103
S-max 5 6 11 S-max 30 30 60
Totals 107 117 224 Totals 105 88 193
p-value ns p-value ns
m+/p+ B1 SD Totals m+/p- B1 SD Totals
ws 12 45 57 ws 15 19 34
W-max 90 48 138 W-max 60 55 115
S-max 5 23 28 S-max 30 47 77
Totals 107 116 223 Totals 105 121 226
p-value < .0001 p-value ns
m+/p+ B1 SD1 Totals m+/p- B1 SD1 Totals
ws 12 13 25 ws 15 9 24
W-max 90 77 167 W-max 60 74 134
S-max 5 12 17 S-max 30 31 61
Totals 107 102 209 Totals 105 114 219
p-value ns p-value ns
m+/p+ SD1 SD2 Totals m+/p- B1 SD2 Totals
ws 12 4 16 ws 15 21 36
W-max 90 96 186 W-max 60 54 114
S-max 5 27 32 S-max 30 46 76
Totals 107 127 234 Totals 105 121 226
p-value .0001 p-value ns
Table S3
m+/p+ m+/p- Totals
Type I 28 16 44
Others 119 58 177
Totals 147 74 221
p-value ns
m+/p+ m+/p- Totals
Type II 105 22 127
Others 42 52 94
Totals 147 74 221
p-value < .0001
m+/p+ m+/p- Totals
Type III 14 36 50
Others 133 38 171







































5'- GAACATCATCCCTGCATCCA 5'- CCAGTGAGCTTCCCGTTCA
5'- GCGAGCAGCTGCAAAGCATCTAAT 5'- AGCTTGCTCCTTTCTTGGAGGGAT
5’- GGTAGAGGTGCACAGCAGGT 5'- CACAGAAGACGAAGAGCTGGA



















GAPDH 5’ – CCCAGCCAAGTTTGAAAGGG – 3’5’ – GCATCTCCCTCACACACCTCTT – 3’ 
CHIP Primers
5’ – TCCTTTGCTGGGGAAACTGT – 3’5’ – AGAGAGGAGTATGGGTGGGT – 3’





Peg3 5’ – GGGGAGTGCTACCTTCTTGA – 3’ 5’ – CTGTTTTGCTCACACCCAAG – 3’
Snord116
Snrpn/Snurf
Gapdh 5’ – GAACATCATCCCTGCATCCA – 3’ 5’ – CCAGTGAGCTTCCCGTTCA – 3’ 
5’ – TGCTTGGATCGATGATGATTT – 3’ 5’ – CTGGACCTCAGTCACGATGAT – 3’ 
5’ – CAGCAATCATGACTGTGGGTA – 3’ 5’ – TCTTTGGCTTGATCTTCCTGA – 3’
RATS primers
FORWARD REVERSE
5’ – AACCTTCCTTCTACAAAGGTTCC – 3’ 5’ – CAGCTCCGTGCAACAGTTC– 3’
5’ – CACAAAGAACACAGGCTCCA – 3’ 5’ – TTCCCTCTTTTCCTGTGTGG – 3’ 
